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ABSTRACT
 Over-modulation of the sympathetic nervous system and reduced heart rate 
variability (HRV) are commonly overlooked components of pain, poor cognition 
(decreased attention, recall, and cognitive processing), depression, stress, and 
fatigue. HRV Biofeedback (HRVB) training induces HRV coherence to balance the 
autonomic system. Paced breathing (~6 breaths/minute) increases HRV 
coherence.   This randomized, controlled intervention trial tested the hypothesis 
that HRVB would improve HRV coherence, pain (severity, interference, and 
catastrophizing), cognitive performance, and reduce depressive, stress, and 
fatigue symptoms and pain medication use in veterans. Participants were 
randomized to previously established HRVB or control protocols. Each participant 
completed a Baseline Assessment, 6 weekly training sessions, a Post-training 
Assessment, a Booster training session and Assessment (1-month post-training), 
and a Follow-up Assessment (2-months post-training). Outcomes included: 15-
minute resting HRV recordings (HRV Coherence Ratio), Brief Pain Inventory 
(severity, intensity), Pain Catastrophizing Scale, pain medication use, Paced 
Auditory Serial Addition Test (PASAT), Hopkins Verbal Learning Test-Revised 
(HVLT-R), Psychomotor Vigilance Task (PVT), Beck Depression Index-II (BDI-II), 
Perceived Stress Scale, and Multidimensional Fatigue Inventory. To date, 85 
patients completed Baseline Assessment, 63 completed Post-training 
Assessment, and 50 completed the 
vi 
entire protocol. Patients in the HRVB group had elevated HRV Coherence Ratios 
at the Follow-up Assessment relative to baseline (0.17±.02 vs. 0.45±0.08, 
p<0.001), whereas no differences were observed among controls (0.17±0.02 vs. 
0.19±0.03, p=0.55). Compared to baseline scores, the Follow-up Assessment 
resulted in a reduction in Pain Interference scores (5.67 ± 0.19 vs 4.69 ± 0.37 
p=<0.01) and an improvement in Mean Reaction Time (431.59 ± 17.32 vs 407.50 
± 17.71, p=0.04). No statistically significant differences were noted among 
controls. The intervention was received, a statistically significant increase in the 
HRV Coherence Ratio was observed in the intervention group over time, whereas 
no changes were seen in the control group.  Those in the intervention group 
improved their reported pain and depression symptoms, reduced non-steroidal 
anti-inflammatory medication use and reaction time as compared to the control 
group. Non-pharmacological therapies that improve pain, cognition, and 
depression would benefit veterans. HRVB is a valid, quantifiable, easily-
implemented intervention. Results from mixed effects statistical models testing 
study hypotheses indicate the potential benefit of HRVB in this trial.  
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CHAPTER 1 
INTRODUCTION AND SPECIFIC AIMS 
 
1.1 INTRODUCTION 
Heart rate variability (HRV) has repeatedly been used to characterize 
current health status and to predict future outcomes.1 Wide variation in heart rate 
throughout each day is reflective of a higher level of resilience and ability of the 
human body to respond to both internal and external stresses. Conversely, minimal 
variation of heart rate has been tied to inflexibility of the autonomic nervous system 
(ANS) to respond to stresses.2 Reduced HRV has been associated with cardiac 
death3, chronic pain,4, 5 mental health disorders,3, 6 along with reduced cognitive 
function.6 7, 8  Over time, this may lead to chronic health issues which may cost 
billions of dollars annually in direct and indirect costs.9, 10  It is estimated that by 
the year 2030, crude (age-unadjusted) prevalence of cardiovascular disease will 
make up 40.5% of the United States adult population (age 18+ years) with around 
$818 billion in direct healthcare cost and around $276 billion indirectly due to loss 
of productivity.10 The ANS plays a role in cardiac function. Therefore, if cardiac 
autonomic function is poor, then heart failure and death may result,3 thus leading 
to a shortened life expectancy, fewer productive years of employment, and a low 
quality of life.  
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As a result of ANS dysfunction, decreased HRV has been associated with 
chronic pain,4, 11 and with decreased cognitive performance,4, 12 as well as 
prolonged recovery in those who sustain concussion.5  Chronic pain is associated 
with changes in cognitive performance.13 Chronic pain has been defined as pain 
lasting more than three months. Approximately one-fourth of the general 
population seeks treatment for chronic pain through their primary care providers.14, 
15 While both pharmacologic (i.e., acetaminophen, nonsteroidal anti-
inflammatories, and opioids) and nonpharmacologic treatments are provided to 
treat pain and other conditions, opioid prescriptions have been provided to millions 
of people across the United States to treat pain.16 In 2012 approximately 25 million 
US adults noted having pain during the 2012 National Health Interview Survey.17  
According to the Veterans Administration, the Department of Defense, and 
the Centers for Disease Control and Prevention, more than 200,000 people died 
between 1999 and 2016 due to prescription opioid overdose.16  The prevalence of 
opioid prescriptions has risen among veterans from 18.9% to 33.4% between 2004 
and 2012.18 This rise in prescription prevalence increased  nearly 77%.18 Deaths 
in 2016 were five times that of opioid related deaths in 1999.19  As concern of the 
opioid epidemic18 grows due to potential for addiction to medications and 
unintended consequences, safe, non-addictive alternatives are needed that can 
be used anywhere, under circumstances that may reduce injury and illness. HRVB 
will be evaluated here as a potentially safe, non-addictive intervention in a 
randomized controlled trial to determine if it is effective at restoring autonomic 
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balance by decreasing pain and improving cognitive function and psychological 
well-being among veterans. 
 This dissertation included three aims within a unique population and source 
of data. The first chapter provides the introduction and specific aims. Chapter 2 
provides the background information, rationale for the proposed specific aims and 
defines the study population. Each of the three specific aims utilized a population 
of United States military veterans over the age of 18 who have chronic pain and 
are registered patients of the William J Bryce (WJB) Dorn Veterans Health 
Administration in Columbia, South Carolina. This document is formatted with 
Chapter 3 describing the methods, Chapter 4 describing the results for the 
outcomes, and Chapter 5 providing discussion for the outcomes. 
SPECIFIC AIM 1: HRVB AND CHRONIC PAIN 
HRVB is thought to be a safe, effective, non-habit-forming intervention to 
reduce pain4, 20-23. This involves coaching a participant to breathe about 6 breaths 
per minute. When using paced breathing, also referred to as resonance frequency 
breathing, through the technique of HRVB, studies have shown a balancing or 
entrainment of the ANS referred to as HRV coherence.24 HRV coherence 
enhances the parasympathetic vagal tone thus allowing the body to establish ANS 
homeostasis in those with increased sympathetic activity.24 Paraphrasing Porges, 
homeostasis is  a dynamic regulation within a functional range for living systems 
to maintain internal states.2 With the application of biofeedback, participants have 
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been shown to improve HRV, improve sleep, cognitive function, and reduce pain.4, 
24  
     This randomized controlled intervention trial examined the efficacy of HRVB to 
reduce pain (severity, interference, and catastrophizing), improve cognitive 
function, and reduce reported symptoms of depression, stress, and fatigue among 
U.S. military veterans with chronic pain utilizing volunteer veterans at the WJB 
Dorn Veteran’s Health Administration in Columbia, SC. Two arms were used 
where a control group was compared with an HRVB intervention group. First, we 
examined if receipt of the intervention (HRVB) was successful in the Intervention 
group by assessing outcomes of HRV parameters using a linear mixed model with 
group, time, group by time interactions. Next, the primary dependent variables 
were pain severity (PS), Pain Interference Score (PIS), and Pain Catastrophizing 
Scale (PCS). These measures were reported using a linear mixed model with a 
group, time, group by time interaction.  Lastly, we evaluated pain medication 
usage. This was categorized based on the type of medication (i.e. Non-Steroidal 
Anti-Inflammatory Drug, Opioid, etc.) evaluated using a linear mixed model with 
the same group, time, group by time interaction. Socio-demographic (i.e. gender, 
race, income, education, etc.) baseline differences were examined for 
confounding; any differences that existed were controlled for in the regression 
models.  
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The research aims and hypotheses for HRVB and Pain were:  
1.1.1 Quantify the changes in HRV time and frequency domain measures among 
the Baseline, Post-Training, and Follow-up Assessments using 
biofeedback. Hypothesis: HRV will improve in the intervention group 
through the receipt of HRVB over time as compared to baseline.  
1.1.2 Evaluate changes in pain resulting from improvement in HRV. Hypothesis:  
Improvements in HRV scores and coherence will result in a decrease in 
pain severity and intensity which will be measured from Pain Severity Score 
(PS) and Pain Interference Score (PIS) over time as compared to baseline.   
1.1.3 Elucidate differences in pain catastrophizing and in pain medication use.  
Hypothesis: There will be a decrease in the Pain Catastrophizing Score 
(PCS) and a reduction in pain medication use using HRVB over time as 
compared to baseline. 
 SPECIFIC AIM 2: HRVB AND COGNITIVE PERFORMANCE  
 Reduced HRV has been associated with poor health outcomes, indicative 
of reduced resilience in responding to physical and psychological stress,25 and 
diminished cognitive function.4  With the application of biofeedback, participants 
have been shown to improve cognitive function.4  
      This study used the same veteran population described above from 
Columbia, SC. Dependent variables were cognitive function outcomes as 
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measured separately by the Paced Audio Serial Addition Test, the Hopkins Verbal 
Learning Test-Revised, and the Psychomotor Vigilance Test.  
The research aim and hypothesis for HRVB and Cognitive Performance was:  
1.2.1 Quantify the changes in Paced Audio Serial Addition Test (PASAT), 
Hopkins Verbal Learning Test-Revised (HVLT), and Psychomotor Vigilance 
Test (PVT) reaction time and total number of lapsed (missed) response 
measures between Baseline, Post-Training, and Follow-up Assessments 
through the use of HRVB. Hypothesis: The number of correctly added pairs 
of PASAT numbers will increase, the mean HVLT score for the number of 
words correctly recalled will increase, the PVT reaction time will improve, 
and the total number of PVT lapses will decrease in the intervention group 
through the receipt of HRVB. 
 
SPECIFIC AIM 3: HRVB, DEPRESSION, FATIGUE, AND PERCEIVED STRESS 
Stress has been linked to negative changes in health such as elevated blood 
pressure and heart rate, increased inflammation, changes in the immune system 
and nervous system, along with depression, and anxiety.25 Stress has been 
associated with developing illness from viral infections such as the common cold 
or influenza.26 Increased psychological stress has been associated with lower 
HRV. HRVB can help reduce depressive symptoms, anxiety, and stress.25 HRVB 
has been suggested to improve symptoms of depression,27-40 stress, 25, 41-43 and 
fatigue.44,45 
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This study assessed subjectively-reported depression, perceived stress, and 
fatigue in U.S. military veterans with chronic pain utilizing the same veteran 
population as previously described for aims 1 and 2. The primary dependent 
variable was self-reported depression, quantified using the Beck Depression 
Inventory-II (BDI).  Depression was assessed using a linear mixed model with a 
group, time, group by time interaction. A second outcome was perceived stress 
score (PSS). A third outcome was self-reported fatigue using the MFI. Separate 
analyses were conducted to assess for General Fatigue, Mental Fatigue, Physical 
Fatigue, Reduced Activity, and Reduced Motivation utilizing the same linear mixed 
model described previously.  
The Research aim for HRVB, Depression, Stress, and Fatigue was: 
1.3.1 Elucidate differences in depression, perceived stress, and fatigue. 
Hypothesis: There will be a decrease in the Becks Depression Inventory 
(BDI), less perceived stress, and a decrease in the general fatigue, mental 
fatigue, physical fatigue, less reduced activity, and less reduced motivation 
through receipt of the intervention HRVB.  
           
  
 
8 
CHAPTER 2 
BACKGROUND 
2.1.1 Heart Rate Variability and Biofeedback 
The human heart rate is the pace at which the heart responds to stimuli 
throughout the day.  This is driven by signals from the ANS46-48  which is comprised 
of two drivers: the sympathetic (action) and parasympathetic (rest) systems.2  The 
ANS is a network of neurological signals sending and receiving messages from 
the brain and other organs. Neural control for both sympathetic nervous system 
(SNS) and parasympathetic nervous system (PNS) originate in the brainstem. The 
sympathetic system primarily responds to stimuli external to the body with the 
mobilization of metabolic resources while the parasympathetic system primarily 
responds to changes within the body to maintain homeostasis, allowing for rest 
and recovery.2 Heart rate fluctuates continuously by adjusting to stresses from the 
surrounding environment. These rate alterations are also referred to as 
oscillations.1, 48 Respiratory sinus arrhythmia (RSA) is the change in HR that 
occurs with each breath; the heart rate accelerates with inspiration and slows with 
exhalation.2, 20  Messages transferred via efferent vagal pathways promote 
parasympathetic control and are thought to decrease inflammation, improve gas 
exchange in the lungs, and promote resilience and resonance.   
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HRV measurements can be obtained to assess the balance in the SNS and 
PNS through short-term or long-term (24-hour) recordings of heart rate. The 
recordings produce variables in time domain49 and frequency domain50 that may 
assist in determining health status.  Normative values of these heart rate variables 
have been established in children51, 52 and adults53 using standard bandwidths,8 
as introduced by McCraty.7 
 As described by Jarvelin et al., in an electrocardiogram, the peak of a 
normal QRS complex is the R wave.  The distance from one R-wave to the next 
R-wave is a time interval and will vary from beat-to-beat.  Variation in the distance 
between successive heart beats over time is called HRV and may provide objective 
findings.54-56 The R-R interval has also been referred as N-N (normal-to-normal).54  
Changes in or lack of changes in variation may be reflective of both psychological 
as well as physical stimuli placed upon the human body and how well the ANS 
reacts to the stimuli.57  Essentially, the greater the variation, the better one is able 
to respond, thus exhibiting better overall health.56, 58 Anything that affects the ANS 
such as psychophysiological stress or recovery of the ANS should be evaluated 
as it relates to HRV54.  Such things that influence HRV include age,59, 60 fat mass,52 
gender,59, 60 cardiorespiratory fitness,61 physical fitness,52  health,59 medication,59 
circadian changes,46 and smoking.59    
As noted by Lehrer et al.,62 the field of psychotherapy evolved out of 
necessity during World War II where physicians were the primary provider of 
psychological care. Over time as the field of psychology and later behavioral 
psychology developed, deep breathing and muscle relaxation techniques were 
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found to be beneficial in treating individuals with anxiety, sleeping difficulty, 
headaches, and high blood pressure.62 These techniques emphasized the use of 
abdominal breathing for breathing retraining.62  Hyperventilation has been 
attributed to the use of thoracic muscles during breathing and Lehrer et al. noted 
that many authors have cited the use of thoracic breathing as being associated 
with both emotional difficulties and complaints of the body.62  While relaxation 
techniques may attenuate SNS activity and feelings of anxiety and frustration, 
during the 1980s and 1990s, Russian scientists were exploring the use of resonant 
frequency breathing to provide more flexibility within the PNS.62 Hyperventilation 
involves an increase in breathing rate often accompanying stressful events, 
whereas controlled breathing at a rate of around 6 breaths per minute leads to an 
increase in positive emotion62, 63 as well as increased HRV.  Changes in HRV has 
been attributed to changes in health.5   Increased variability is associated with 
improved health39 whereas decreased HRV has attributed to decline in health.  
Decreased HRV has been associated with depression as well as with the use of 
antidepressant medication.41 HRV has been evaluated in adults to monitor 
outcomes after significant events and even predict outcomes over several 
decades. Since the 1970s, examples include congestive heart failure,64 post 
myocardial infarction, alcoholism, and diabetic neuropathy.46   
When synchronization between the heart, lungs, and brain is reached, HRV 
coherence develops.24 HRV coherence can be achieved using a paced-breathing 
technique called resonance frequency breathing.24 Each person has a unique 
frequency in which parasympathetic control is promoted and HRV coherence is 
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achieved, which usually occurs at ~6 breaths per minute (or 0.1 Hz). 20, 36, 65   
Coherence refers to oscillations (heart rate and respiration) that occur at the same 
frequency. When resonance frequency breathing is achieved, oscillations in heart 
rate and respiration appear, are in phase, and HRV coherence is maximized.7 
McCraty et al refer to HRV coherence as “an optimal psychophysiological state”.66  
This frequency maximizes efficiency of gas exchange in the lungs, may lower 
blood pressure, improve depression and anxiety, decrease pain, improve athletic 
performance20 and increase HRV.9 As quoted by Swanson et al. “Increased HRV 
is synonymous with parasympathetic tone or vagal tone”.9 Reduced HRV has been 
associated with poor health outcomes and is indicative of reduced resilience in 
responding to physical and psychological stress.  Those with positive affect 
(positive thought processes) performed better with HRVB in cognitive tests 
suggesting that positive thoughts influence the benefit of HRVB67 which is 
consistent with other investigators who have stated that negative thoughts can 
drive  negative results and conversely with positive thoughts and outcomes.68 
Porges notes that this technique influences the parasympathetic nervous system 
through activation of the nerve fibers which regulate blood pressure and heart 
rate.69 HRVB is a non-pharmacological treatment in the reduction of chronic pain,4 
has influenced vagal activity,65 and inhibits spinal column pain pathways.4 HRVB 
has been shown to improve anxiety,37-39, 70-72 improve sleep and cognition with 
decrease in stress and pain,4, 21-23, 39, 73-75 decrease blood pressure,76, 77 
depression,32-41 insomnia,78  heart disease,9, 79 asthma,80-82 and posttraumatic 
stress disorder (PTSD)8, 36, 83  
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 2.1.2 HRV, HRVB and Chronic Pain in Veterans:  
Pain has been labeled as the fifth vital sign in the past few decades, has 
been used as a subjective measurement, and appears to be noted with more 
frequency in the news. Pain not only interferes with activities of daily living and 
quality of life,84-86 it is one of the leading reasons for primary care visits.87, 88   
Treatment for pain has led to stronger, more potent, and potentially addictive 
medications to be prescribed in higher quantity and in frequency to the point that 
the world is facing an opioid epidemic.89, 90 Despite the increase in treatments, pain 
appears to be worsening globally, not improving. Chronic pain is defined as pain 
that lasts longer than three months14, 15 and has been shown to disrupt sleep, 
cognitive function, increase fatigue and depression. It is thought that each year, 
over 100 million people seek treatment for chronic pain in the US resulting in 
medical costs near $635 billion both directly and indirectly.91 Of those taking opioid 
narcotics for chronic pain, upwards of 60% may be prone to abuse.92 In 2015, it 
was estimated over 2 million Americans had a prescription pain medication abuse 
disorder while nearly 600,000 used heroin.93 The average annual cost for opioid 
rehabilitation with methadone is approximately $4,700 per patient.94 
Military recruits are medically screened out of the general population and 
tend to be healthier than the general population95 whether the individual was 
drafted or volunteered. Veterans comprise approximately 10% of the US 
population.96  During their time in service, military personnel have access to 
comprehensive health care95 with routine maintenance and care provided for 
exposure to both combat related and non-combat related injuries and illness.95 
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However, following military service, veterans tend to report higher chronic pain 
than the general population.97-100  
Among age-matched veterans and nonveterans, those who have provided 
military service tend to express higher chronic health and psychological concerns 
than nonveterans.99 Among some of the symptoms, veterans who deployed for the 
Persian Gulf War (1990-91) have a higher prevalence of abdominal pain,101-103  
and pain in the joints relative to veterans that did not deploy during that time101-107  
and higher prevalence of arthritis,98, 108-112  backpain,103-105, 111 fibromyalgia,109 and 
headache102, 106 in veterans relative to nonveterans.  This is most striking among 
those engaged in conflicts in Iraq and Afghanistan and has been shown to interfere 
with activities of daily life (ADLs).113, 114  
Pain in veterans has been associated with physical and mental problems.4  
Opioid and opioid receptor binding medications are standard for use in chronic 
pain and have been associated with physical or psychological side-effects ranging 
from constipation, nausea, and intolerance to the medication, as well as 
addiction.115  Opioid prescriptions are more likely to be prescribed for pain to 
veterans with mental health conditions than to veterans without mental health 
conditions.116  
A relative increase of 76.7% in opioid prescriptions among veterans 
increased between 2004 and 2012 from 18.9% of all veteran outpatients to 
33.4%.117 This increased usage of opioids has the potential to alter cognitive 
performance. In a study by Sinnot et al.,29 between 2000 and 2007, low back pain 
prevalence rate increased 4.8% as compared to diabetes 4.4%, hypertension 
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4.1%, and depression 3.8% among VA users. The rate in number of individuals 
with low back pain rose from 10,955 to 15,205 per 100,000 Veterans 
Administration (VA) users.29  Quality of life relating to health among active duty 
men has been reported by Barret et al., to be more likely to be physically limited 
from activity, report pain, and report inadequate rest as compared to men who 
have no military service.113 Further, the authors note active duty men to be five 
times more likely to have pain and limited activity for 14 or more days as compared 
to men with no military service.113 Orthopedic injuries leading to limited physical 
activity and chronic joint symptoms may be associated with increased prevalence 
of arthritis among veterans as compared to nonveterans.108   
Pain has been associated with changes in HRV23, 39 and with changes in 
memory.30 In a study of older adults by van der Leeuw et al., women, African 
Americans, and those with fewer years of education were more likely to have pain 
interference or severe pain.118 Pain severity was found to produce more disability, 
especially beyond the age of 65.84 It is conceivable that a reduction in pain may 
also facilitate improvement in memory.  HRVB has been shown in studies to be an 
effective tool in reducing pain in veterans.4 Therefore, HRVB may be effective at 
improving both pain and memory.  
2.1.3 HRV, HRVB, and Cognitive Function in Veterans 
According to the Centers for Disease Control and Prevention (CDC), it is 
estimated that over 16 million people in the U.S. have some form of cognitive 
impairment (more than twice the population of New York City) and over 10 million 
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family members provide care for these individuals.119 Cognitive impairment may 
range from mild to severe in which changes may be noted in difficulty 
concentrating, trouble remembering or learning.119  
Working memory is believed to correspond to activity within the prefrontal 
cortex (PFC).120  In times of stress, the PFC may be bypassed or taken offline 
allowing the amygdala to take over and respond to threats, then return to PFC 
control when the threat subsides for deliberate and conscientious behavior.121  This 
inhibitory control is associated with executive function, emotional control, along 
with working memory.121 Normally, the amygdala can be associated with fear or 
response to threats.  When the PFC is online and working appropriately, while it 
may not suppress fear, it may help to remember strategies to contend with fear.55 
Thayer et al. suggest that when the PFC goes offline, more energy is mobilized by 
the amygdala to be able to respond to perceived threats and a decrease in HRV 
has been noted.55 Cognitive performance and the PFC have been linked with 
HRV.122 An intact, activated PFC with vagally-mediated HRV demonstrated 
increased executive function, increased correct answers, and faster reaction times 
in several studies with HRVB.122-124  
In a study by Stricker and colleagues, memory impairment was more likely 
in those with PTSD.125 Among veterans of the Persian Gulf War (1990-1991), 
those with PTSD performed more poorly than those without PTSD in tests 
measuring attention, learning, and memory.126 In a prospective cohort of over 
1,200 active duty U.S. Army Soldiers of the Iraq conflict (2003-2005), study 
participants conducted pre- and post-deployment assessments. Those who 
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deployed were found to  display more tension and confusion, decreased sustained 
attention, decreased verbal learning, decreased visual-spatial memory, yet 
exhibited increased reaction time.127 In a stratified, retrospective cohort of over 
181,000 male veterans without dementia, participants were followed from 1997-
2007. The 7-year cumulative incidence rate (CIR) for dementia among those 
participants with PTSD had a CIR of 10.6% as compared to those without PTSD 
with a CIR of 6.6%. Those with PTSD had nearly 2-fold incident dementia utilizing 
Cox proportional hazard models.128    
Weiner et al. noted that a decline in memory and learning was found in 
those with chronic back pain129  and chronic pain was associated with changes in 
memory and emotional decision-making tasks.30, 130 Cognitive functions are 
thought to change in accordance with chronic pain, in which pain may be a 
distraction from required attention leading to poor cognitive outcomes.131  It is also 
believed that education may be protective in preventing cognitive decline and 
influences neuropsychological performance.132-136 
In a quasi-experimental study design of 37 male Norwegian sailors, upon 
completion of eight weeks of basic training, participants were transferred into a 
training program for another eight weeks. Assignment to fitness training versus a 
fitness detraining was based on their follow-on duty assignment. Those who 
maintained fitness training continued three hours per week of physical fitness 
whereas those in the detrained group went on-board ship for service. Those in the 
fitness trained group demonstrated higher HRV, faster reaction time in executive 
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functions, and provided more correct answers in an N-back test, recalling numbers 
previously seen.122 
In another study by Hansen et al., 53 Norwegian male sailors provided a 5-
minute baseline HRV recording. HRV categories were split with the median of 
RMSSD. The high HRV group demonstrated faster mean reaction time, fewer 
errors, and more correct answers than the low HRV group.124 
Prinsloo et al, reported using a randomized HRVB and control group study 
in 18 male participants with work-related stress.  Upon enrollment, participants 
were stratified randomly based on age initially and then later randomly allocated 
to either the HRVB or control group. Participants were taught how to use an 
electronic handheld biofeedback device, to follow a wave form with inhalation and 
exhalation using time-domain metrics rather than true resonance frequency 
breathing. Baseline recordings were obtained including blood pressure and heart 
rate. This was followed by a five-minute Stroop task (responding to squares and 
color words in different colors), a five-minute rest period, and finally the ten-minute 
HRVB intervention. Those in the HRVB group made fewer mistakes and improved 
reaction time as compared to the control group.123  
In a cross-sectional study of middle-aged male twins in the Emory Twin 
Studies from the Vietnam Era Twin Registry, participants remained on the Emory 
campus, provided 24-hour leisurely ambulatory HRV recordings, and conducted 
BDI and cognitive testing. HRV was positively associated with verbal memory.137 
Twin HRV recordings of less than 18 hours were excluded.  Sutarto and colleagues 
 
18 
reported among thirty-six operators randomly allocated into HRVB or control 
group, participants were provided five-weekly HRVB sessions of 30-50 minutes 
each. Improvement in attention and memory were noted in recipients of HRVB.138 
2.1.4 HRV, HRVB, and Depression in Veterans 
In the U.S. in 2012, direct cost of $300 billion was spent on mental health.139 
In the Department of Veteran’s Affairs in 2010, over 110,000 primary care visits 
had new incidence of depression in veterans.140 The veteran population comprises 
approximately 18 million people of the U.S. population141 and major depression in 
veterans is estimated to be between 12-30%.142 A recent publication by Liu et al. 
reported depression prevalence among U.S. military veterans increased from 9% 
(2007-2008) to over 14% (2015-2016) based on a sample from the National Health 
and Nutrition Examination Survey (NHANES) and over 16% of veterans reported 
having little energy over half the days in a two-week period.139  
   Arnsten and Goldman-Rakic described that the PFC may go off-line when 
under stress for survival purposes however when sustained, this may be not be 
conducive for society as the PFC helps with executive control and inhibition143 This 
sustained off-line process can lead to psychological disorders to include 
depression, anxiety, and PTSD.144 What’s more is that reduced HRV is connected 
with depression.32, 144, 145 Reduced HRV has been reported with depression in both 
healthy and unhealthy populations146-148 and it has been improved through the use 
of HRVB.35, 36, 40, 41, 146, 149 In a randomized controlled trial of 38 participants (ages 
18-70 years) with unexplained somatic complaints, HRVB training over the course 
of 10 weekly sessions helped resolve depressive symptoms as early as 5 weeks 
 
19 
after treatment.35 Depression has been associated with chronic pain,29, 30 
concussions,27, 28 cardiovascular risks,150 and is observed in children with 
anxiety.31 Depression has been associated with heart failure and improved HRV in 
heart failure patients146 has demonstrated improved survival151 and better 
outcomes.152 However, one study suggested the direction for the development of 
depression was due to reduced HRV, whereas in the presence of antidepressants, 
depression reduced HRV.153 
2.1.5 HRV, HRVB, and Stress in Veterans 
In a review by Subhani et al.,154 stress is believed to be associated with 
impairment of memory,155 and changes in cognitive health156 possibly resulting in 
atrophy of the PFC and hippocampus.157  As the PFC has been connected to 
attentional endurance, changes in executive function may displayed.158 The link 
between the PFC and the heart may reside in both direct and indirect pathways 
which control the heart rate via the vagus nerve. This PFC-cardiac connection 
effects the PNS and SNS as well as influence baroreceptors to modulate HRV. 158 
This interaction with the baroreceptors has been associated with increased mental 
workload and cognitive demand.158-160  Cognitive function can be impaired by 
chronic psychological stress.123, 161-163 Chronic stress has been associated with 
major depression and PTSD, especially in military veterans.142 PTSD in veterans 
ranges from 6-31% as compared to 6-12% of the U.S. population.142 As women in 
the military in past conflicts may have been relegated to nursing or clerical roles, 
more recent conflicts have exposed women to greater combat intensity.142 Since 
past medical studies have examined combat-related stress in male veterans, this 
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new dynamic may be considered in future studies including more women.  The 
World Health Organization has referred to stress as a nonpsychotic mental health 
disorder164 and even provided a diagnostic classification code for this. Chronic 
psychological stress has been associated with reduced HRV.123, 165-168 Some 
occupations demand intense mental focus and workload such as air traffic 
controllers, pilots, and surgeons. Utilizing the National Aeronautics and Space 
Administration Task Load Index (NASA-TLX), subjective mental load has been 
measured and has demonstrated correlation of HRV to both reduced attention and 
mental fatigue.158 When time-on-task was recorded, lower HRV was found with 
longer tasks requiring sustained vigilance and attention.158  HRVB is believed to 
help reduce stress.41-43 Prinsloo et al., reported participants in an HRVB group felt 
more relaxed and alert.123  Slowed breathing with the abdomen has been found to 
increase HRV and reduce anxiety in musicians.43 Pregnant women who completed 
HRVB training reported reductions in stress compared to women who did not 
receive HRVB.42 
2.1.6 HRV, HRVB, and Fatigue in Veterans 
Fatigue is experienced by many people, but they often find it difficult to 
describe. Persson and Bondke Persson described fatigue as subjective and vague 
but provided three characteristics: develops gradually, while different than 
weakness is relieved by rest, lasting more than six months.169  Smets et al. 
describe fatigue as one of the most commonly reported symptoms in cancer 
patients and that fatigue is a symptom often relieved via convalescence.170 
Schiehser et al. depict fatigue as being a multi-faceted entity with physical and 
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mental components, involving alterations in motivation, initiating and sustaining 
tasks, and may be associated with trauma such as traumatic brain injury, 
depression, and anxiety.171 Fatigue is often a symptom described by healthy 
people after being sleep restricted, after physical exertion, or in post-surgical 
patients172. Fatigue is associated with outcomes of the Psychomotor Vigilance 
Task, even among those who are not injured.173 While fatigue is a common 
concern expressed to medical providers, it can also be a precursor to diseases or 
disorders.172 Fatigue is experienced in approximately 38% of community dwellers 
and the prevalence of fatigue lasting more than six months in the general 
population may range from 2-11% at any given time.174 HRV is reduced with 
fatigue175 and has been noted to be lower due to both mental effort and workload 
associated with fatigue.166, 176, 177 Difficulty with concentration and memory 
comprise mental fatigue, is common with concussion173 and in workload.178  Mental 
effort and HRV power have been found to be inversely related126, and relationships 
between HRV, mental workload, and mental fatigue have been reported.176, 179 
Reduced HRV has been reported following physical or cognitive challenges as 
well.180 HRVB has demonstrated improvement in both fatigue and in depression.44 
Reduced motivation to initiate activity may be described in those who report feeling 
fatigued along with depression.172 A study found improved motivation among 
police officers who received HRVB. 45 A separate study found improvement in four 
of five fatigue subscales after HRVB. Improvements were reported in general 
fatigue, mental fatigue, physical fatigue, and reduced activity; however, 
improvements were not observed in reduced motivation.44 
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In summary, HRV has been shown to be reduced in those with poor health 
and health outcomes whereas increased HRV has been associated with better 
health outcomes. Veterans have suffered disproportionately relative to the general 
population. Veterans have worse health outcomes, report more pain, and use more 
pain medication relative to the general population. Veterans have worse cognitive 
performance, depression, stress, and fatigue relative to the general population. 
HRVB has been shown to improve HRV, both in the general population and in 
veterans, and HRVB has been shown to improve health outcomes. Results from 
this analysis provide evidence that HRVB can improve HRV, decrease pain 
severity and interference, reduce the number of non-steroidal anti-inflammatory 
drugs used, decrease reaction time, and decrease depression. 
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CHAPTER 3 
METHODS AND MATERIALS 
Project Design 
 This study was a randomized sham-controlled pilot intervention trial using a 
standardized HRVB protocol for the intervention group and a sham condition for 
the control group of chronic pain patients over a 16-week intervention period. This 
study was approved by the WJB Dorn Veteran’s Administration Institutional 
Review Board as well as the University of South Carolina Institutional Review 
Board.  The study was funded by the Veterans Affairs Office of Research and 
Development (Grant number: I01BX007080) and was registered as a clinical trial 
(NCT 02426476). 
The design of this study included four assessments over a 16-week period 
(Appendix A, Figure A1). The initial visit included informed consent as well as a 
Baseline Assessment that included depression, stress, and fatigue questionnaire 
data, a 15-minute resting HRV recording, computer-based cognitive assessments, 
and saliva sample collection. Upon completion of informed consent, participants 
were randomized into one of two groups: HRVB intervention group or a control 
group. Each participant returned for weekly training visits over a period of six 
weeks. Participants returned on week seven for a Post-training Assessment which 
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repeated the same measurements as the Baseline Assessment. A month later, 
participants returned for a booster training session and a third assessment. This 
Booster Assessment included the same questionnaire data and a 15-minute 
resting HRV recording.  The fourth and final assessment was one month after the 
booster, at week 16. This final Follow-up Assessment repeated the same 
questionnaire, HRV recording, cognitive assessment, and saliva collection as the 
first two assessments (Appendix Figure A.1.). 
Study Population 
 The target population consisted of veteran patients attending the WJB Dorn 
Veterans Administration Medical Center (DVAMC) who were: English literate, ≥18 
years old, of any race, ethnicity, or sex who met other inclusion and exclusion 
criteria. Patients were recruited initially from the Dorn VAMC Pain Clinic and later 
from other clinics such as Rehabilitative Medicine, Rheumatology, Primary Care, 
and Physical Therapy. IRB approved brochures along with flyers were placed in 
approved public areas around DVAMC so that volunteers could contact research 
coordinators. The results presented in this dissertation represent data from a 
preliminary sample of study participants collected from June 2016 to February 
2019. Eligibility was checked using a telephone screen when the veteran 
expressed interest in participation in the study. A chronic pain screen was 
performed using the Pain Screening Questionnaire (Vanderbilt University Medical 
Center, Center for Quality Aging, Nashville, TN). Pain was assessed with the 
following questions: 1.) Do you have pain anywhere right now? 2.) Does pain ever 
keep you from sleeping at night? 3.) Does your pain ever keep you from 
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participating in activities/doing things you enjoy? 4.) Do you have pain every day? 
If a caller identified “yes” to questions 1-3 or to question 4, then they were 
determined to have chronic pain. Further eligibility was checked through VA 
medical records.  
 Exclusions targeted medications or medical conditions that could potentially 
bias measures of HRV or the outcomes, or conditions that would preclude protocol 
compliance.  The following exclusion criteria (assessed by self-report and medical 
record review) were applied: a) history of arrhythmias requiring medication and/or 
hospitalization, including supraventricular tachycardia or atrial fibrillation; b) 
Veterans with a pacemaker or automatic implantable cardioverter-defibrillator; c) 
history of an acute coronary syndrome, revascularization, thrombolytic or other 
therapy related to ischemic heart disease; d) uncontrolled hypertension (systolic 
blood pressure >140 mmHg, diastolic blood pressure >90 mmHg), however those 
with well-controlled hypertension with no change in medication in six months were 
not excluded; e) history of heart transplant or cardiovascular surgery within one 
year; f) receiving beta-adrenergic antagonists (beta-blockers); g) receiving non-
dihydropyridine calcium channel blockers; h) those receiving a renin-angiotensin-
aldosterone system antagonist were eligible if medication profile and blood 
pressure were stable; i) New York Heart Association class 3 or 4 congestive heart 
failure; j) history of seizure disorder or use of antiseizure or anticonvulsant 
medication; k) cognitive impairment such as dementia, or a history of acquired 
neurocognitive deficit, or central nervous system or neurological disorder (e.g., 
Gulf War Syndrome); l) moderate or severe head injury or stroke; m) evidence of 
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active substance abuse or dependence (alcohol or tobacco use was not an 
exclusion and this data was collected during the questionnaire); n) life history of 
bipolar, psychotic, panic or obsessive-compulsive disorder (history of depression 
was not an exclusion).  
Upon enrollment, participants signed informed consent and a Health 
Insurance Portability and Accountability Act (HIPAA) medical release which were 
kept on file and a copy was provided to the participant with instructions on how to 
disenroll or contact the Prinicpal Investigator (PI) should they choose to do so. A 
remuneration of $20 per visit was provided ($200 for completing the protocol). 
Later, to increase recruitment and retention, supplement funding was provided 
which included $30 per visit and $10 for travel ($400 max for completing the study). 
Randomization  
 Assignment to either the HRVB treatment or control group was conducted 
using a permuted block randomization procedure with a block size of 4 and without 
stratification prior to Baseline Assessment. For example, in each block, 
permutations could result in six different combinations such as 1-1-2-2, 1-2-2-1, 1-
2-1-2, 2-1-2-1, 2-2-1-1, or 2-1-1-2. The treatment assignment was determined 
before anyone was enrolled and placed in each enrollment packet where it was 
kept in a confidential location. This was a single-blind study in which only the HRVB 
trainer knew the group assignment of each participant. Participants were blinded 
to their group assignment. At the completion of the Follow-up Assessment, those 
in the control group were made aware that they had not received the intervention 
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and were offered a single “cross-over training” as an unpaid training visit to receive 
the HRVB training just as the intervention group.  
Intervention Group Training 
HRVB training was conducted by a certified trainer following a previously 
established, standardized protocol adopted by the Biofeedback Certification 
Institute of America (BCIA).4, 181 Participants in the Intervention group completed a 
Baseline Assessment followed by six weekly training sessions. HRVB training was 
provided by a trainer on a dual-screen in which both the trainer and the participant 
could visual HRVB changes in real-time. The trainer informed participants about 
the connection between resonant frequency breathing and heart rate which was 
reinforced with coaching to find the resonant frequency of breathing. Each weekly 
HRVB training session consisted of a 25-minute resting period that included 
coaching and biofeedback training. Participants were encouraged to “relax” during 
their training sessions, without using their cell phones or falling asleep. HRVB 
training involved two main components. The first was to assist the participant to 
paint a positive mental image of something that truly makes them happy and guide 
their thoughts to a peaceful, reduced-stress environment. The next portion of the 
training included instruction to adjust breathing rate and pattern. Participants were 
taught to perform “belly-breathing” using diaphragmatic breathing, allowing the 
abdomen to distend to allow for the full use of the diaphragm. Participants were 
taught to breathe deeply in through the nose and out through pursed lips, using 
the diaphragm and belly in a manner that the shoulders do not rise and fall. The 
use of good posture without slouching and the use of transitioning breathing 
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between the peak and valley of each breath (inhalation and exhalation) were 
taught. The trainer coached the participants to slow their breaths to about six 
breaths per minute, allowing for the synchronization of heart rate oscillations with 
respiration. This allowed the participant to achieve a state of “HRV coherence”. 
This state could be directly observed on the biofeedback computer monitor by the 
participant and the biofeedback coach. The synchronization of the heart rate and 
breathing was observed as an increase of heart rate oscillations during inhalation 
and a decrease in heart rate oscillations during exhalation. This is also referred to 
as zero phase between heart rate and breathing.   
For home practice, participants were provided a portable plethysmograph 
(emWave2® hand-held personal stress reliever, HeartMath, Boulder Creek, CA) or 
the use of a mobile-application (app) for smart phones (InnerBalance®) of their 
preference for home practice and use between weekly HRVB training sessions. 
Participants were encouraged to use this device for at least 15 minutes per day 
between each weekly training session. Participants were instructed to use the 
device at times of high-stress such as frustration, when preparing for sleep, or 
simply when time was available each day. During subsequent training visits, 
participants were asked how many minutes they practiced on average each day 
and this self-reported information was documented, and files summarizing practice 
time were downloaded from the portable emWave and mobile phone app for later 
analysis.   
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Intervention Group Assessments 
Four assessments were made. The first was during the baseline visit. The 
Post-training Assessment was conducted during the 8th week, the Booster 
Assessment was conducted in the 12th week, and the Follow-up Assessment in 
week 16. Questionnaire data was obtained first. Next, while participants were 
seated in a comfortable position, HRV measurements were conducted over a 15-
minute resting period using non-stimulating nature scenes without any text, images 
would change every 40 seconds as participants practiced focusing their attention, 
resonant frequency breathing, and positive imagery. Third, cognitive testing was 
conducted followed by saliva collection.   
Control Group Training 
To control for the laboratory environment or other potential placebo effects, 
control group participants used the very same training equipment as the 
intervention group however without any HRVB training. During the weekly training 
clinic visits, control participants had HRV and respirations recorded for 15 minutes, 
but no active training, coaching, or biofeedback was provided. Neither heart rate 
nor breathing information was displayed on the monitor during the control group 
sessions. Participants were instructed to “relax” without using cell phone or falling 
asleep. Control-group participants were provided with a stress-squeeze ball to use 
for home practice. They were encouraged to practice relaxing at home daily for at 
least 15 minutes and encouraged to use the issued stress-ball while relaxing.  
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Control Group Assessments 
Control group participants attended the same four Baseline, Post-training, 
Booster, and Follow-up Assessments with the time separation and duration as the 
intervention participants. Questionnaire data was collected. During the passive 15-
minute HRV recording period, subjects viewed the same static, relaxing nature 
scenes on the computer monitor as were presented to the HRVB intervention 
group for assessments. They sat quietly while passively observing non-stimulating 
nature scenes without any text. These images changed every 40 seconds. 
Cognitive tests were conducted followed by saliva collection.  
HRV Outcomes 
Each resting HRV outcome was measured at the four assessments 
(Baseline, Post-training, Booster, and Follow-up) in a standardized manner. HRV 
recording was conducted in an office setting with dimmed lights. Nature slides were 
viewed at each of the assessments during the recording. At baseline, the 
participants were asked to relax. At subsequent assessments, the participants in 
the HRVB group were instructed “Do what you have been trained to do”. No other 
instructions or biofeedback was provided. HRV data was collected with two 
electrodes to the left forearm and one to the right. Respirations were monitored 
using a Piezo-respiratory transducer. Both groups completed a 15-minute resting 
HRV recording with an Acquire ECG encoder.  
Inter-Beat Intervals (IBI) files were exported and processed according to 
established guidelines (Appendix A, Figure A.2).182 Kubios software (Kuopio, 
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Finland) was used to de-artifact raw data and perform a fast Fourier transformation 
of the HRV power spectrum for each data file. Time-domain HRV measures: mean 
heart rate,  SDNN (standard deviation of heart rate N-N intervals) 54,  RMSSD  (the 
square root of the mean squared difference of successive N-N intervals), and 
frequency-domain variables: (Very Low Frequency (VLF), Low Frequency (LF), 
High Frequency (HF) power, Total Power, and Coherence Ratio) were calculated. 
The HRV coherence ratio was obtained by identifying the maximum peak in the 
0.04 Hz to 0.26 Hz HRV range, calculating the integral in a window 0.030 Hz wide 
centered on the highest peak in that region (‘peak power’, usually ~0.1 Hz), then 
calculating the total power of the entire spectrum. The HRV Coherence Ratio (as 
described by McCraty) was quantified as:  peak power / (total power – peak power). 
The frequency range of 0.04-0.26 Hz was selected because it is the range within 
which HRV coherence (i.e. cardiorespiratory entrainment) occurs.7, 8, 58, 66 
Questionnaire Outcomes  
 A structured, self-administered questionnaire was used to obtain 
sociodemographic (age, race, ethnicity, sex, body mass index, education, income, 
marital status), and lifestyle information (pain medication use, alcohol, caffeine 
consumption, tobacco use, circadian preference, employment status) (Appendix 
Figure A.3.). Information obtained from the patient’s medical record included 
chronic pain condition with diagnosis. Symptoms of: pain (BPI),183, 184 depression 
(BDI),185 stress (PSS),186 and fatigue (MFI),170, 172  were obtained at all four 
assessments. Higher scores on each symptom questionnaire corresponded to 
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increased symptom severity. Symptoms were scored in accordance with the 
original documentation accompanying each instrument.  
Pain Outcomes  
Pain was assessed using two instruments: Brief Pain Inventory (BPI)184 and 
the Pain Catastrophizing Score (PCS).187  Originally the BPI was designed for 
cancer patients by the World Health Organization and has since been used in 
many research and clinic settings.183, 188 The BPI has been used for its reliability 
and validity in many languages and used in pain studies.183, 188 The Brief Pain 
Index has been validated as an effective gauge for those who have pain related to 
malignant and nonmalignant disorders.184, 189 This self-reported questionnaire for 
pain severity ranges with a pain-free score of 0 to worst pain of 10. Reliability and 
validity have been demonstrated.183, 190-192 Negative emotion and physical 
inactivity are subscales of the BPI.193 Pain interference was evaluated using the 
BPI with a scale of 0-10 in which 0 is no interference and 10 complete 
interference.184, 194  
Pain was also assessed using the PCS.187 The PCS explores factors that 
impact pain through catastrophizing, was developed from literature for catastrophic 
thinking as it relates to experiencing pain, is written at the sixth-grade level and 
performed in 5 minutes or less. Thirteen items are summed to provide a total score 
for the PCS with a range from 0-52. After reflecting on painful experiences, the 
PCS provides three subscales to assess helplessness, magnification of problems 
and pain, and rumination.  The PCS has been shown to have internal consistency 
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with alpha coefficients for total PCS  0.87, rumination 0.87, magnification 0.66, and 
helplessness 0.78.187  
Cognitive Outcomes 
The PASAT is used to assess processing speed, attention, working memory 
and is influenced by fatigue195. Strongly correlated with education, PASAT has 
demonstrated repeatability and tends to decrease score with increased age195. 
Standardized options for PASAT exist with 29, 50, or 60 summed pairs195, 196.  
Spoken at three second intervals from a recording, numbers were read aloud. The 
participant summed the last two spoken numbers provided by the researcher. The 
total score of correct responses was summed for a maximum score of 29. 
 The Hopkins Verbal Learning Test-Revised (HVLT-R) is a tool used to 
measure verbal and working memory as well as executive functioning through 
immediate and delayed recall of terms.197 HVLT utilizes a list of words that the 
participant hears and then repeats when all 12 have been provided verbally. It is 
scored on a scale of 0-36 in which 0 indicates no correct responses and 36 is the 
max in which all responses were correct.197  As noted, the list of words has three 
themes such as items of clothing, tools, occupations, etc., heard three separate 
times.  At each of the three assessments (Baseline, Post-training, and Follow-Up), 
the participant is provided a different set of words to recall after hearing them.  
Visualization of the words is not provided.  This test can ascertain immediate recall 
from an auditory stimulus.  
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 The Psychomotor Vigilance Test (PVT) is a 10-minute timed test in which a 
participant reacts to a stimulus on a computer screen. The stimulus varies in time 
between 2-10 seconds in between the stimuli. The red dot remains on the screen 
for 1 second198 and the reaction time is measured in milliseconds. The shorter the 
reaction time, the faster the response. A response time more than 500ms is a lapse 
or missed response which may be suggestive of sleep deprivation or inability to 
sustain concentration.  
Depression, Stress, & Fatigue Outcomes 
Depression was measured using the Beck Depression Inventory-II (BDI). 
BDI was established by Beck et al. in the 1960s referencing many psychological 
publications of the time.199  This was updated in 1978 as the BDI-IA200, 201 and in 
1996 as the Beck Depression Inventory-II.200, 201 Normative variables have been 
established for male military veterans with chronic pain which may assist in 
assessing those who have more physical complaints than what is considered to 
be normal and possibly decrease confounding.201 The BDI is a 21-item self-
reported questionnaire to elucidate the severity of depression experienced by the 
reporter following diagnostic criteria established in 1994 by the Diagnostic and 
Statistical Manual of Mental Disorders (4th Edition) (DSM-IV).201   Cutoffs have 
been standardized: 0–9 indicates normal, 10–18 indicates mild depression, 19–29 
indicates moderate depression, and 30–63 indicates severe depression.202, 203  
This test has excellent reliability (Cronbach alpha:0.92),185 and has been validated 
to separate depressed from non-depressed individuals.204 Reported levels in 
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depression/mood were assessed at each of the four previously stated 
assessments through the use of the BDI-II.  
Stress was evaluated using the Perceived Stress Scale (PSS).26, 186 This 
tool was first developed in 1983186 has since been adapted for participants to 
answer questions in a way that causes them to consider different aspects of their 
lives and qualify how stressful and messy they feel their lives may be. Once a 14-
item questionnaire, this questionnaire now has a 10-item negative and 4-item 
positive component. PSS is a self-reported questionnaire where individuals can 
rate their stress. Reliability and validity have been demonstrated.79, 186, 205  Each 
question is based on a 5-point score ranging from (0) to (4) or “never” to “very 
often”. 206 The PSS has been widely used and has been validated in numerous 
languages and populations. It presents data representing the degree to which the 
participant feels out-of-control, feels life is unpredictable, and feels overloaded by 
external factors.186 Seven positive items are reverse-scored and then all questions 
are summed. 186  Reported levels in perceived stress were assessed through the 
PSS at each of the four previously stated time assessments. 
  Fatigue was assessed using the Multi-dimensional Fatigue Inventory (MFI). 
The MFI provides insight to motivation, physical activity, mental and general 
fatigue.  Its 20 questions have demonstrated internal consistency and external 
validity.170, 172  Changes in fatigue and energy level were assessed exploring 
differences in the MFI at each of the previously stated four assessments. 
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Statistical Analysis 
  All statistical analyses were performed using SAS 9.4 (SAS Institute. Inc., 
Cary NC.)  Descriptive characteristics of participants were summarized between 
intervention and control groups. Analysis included demographic and lifestyle 
variables comparing between groups using the Student t test for normally 
distributed continuous variables, the Wilcoxon exact test for non-normally 
distributed continuous variables or Fisher’s exact test of independence for discreet 
variables. Continuous outcomes were compared between groups. To compare the 
main outcomes of interest (HRV coherence, PS, PIS, PCS, pain medication usage, 
PASAT, HVLT, PVT, BDI, PSS, and MFI) with group, time, and group by time 
interaction, linear mixed models were utilized after adjusting for demographics 
and/or lifestyle variables.  
 The process of randomization reduces the possibility of confounding 
between groups. To ensure this was effective, potential confounders were 
evaluated to determine if they were equally distributed among the intervention and 
the control groups. While randomization should remove potential confounding 
variables, demographic characteristics and outcomes measures were evaluated 
using bivariate comparisons between the two groups. Comparisons of categorical 
variables such as gender, race, and income were made between groups of 
baseline sociodemographic, comorbid health diagnoses, and lifestyle choices 
using Fisher’s Exact test (PROC FREQ in SAS). Due to small cell counts, 
American Indian and Other races were combined with African American into one 
category named “Minorities”. Normality of distribution of continuous variables such 
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as age were evaluated (PROC UNIVARIATE in SAS). As depression can impact 
other variables such as pain, the BDI was considered a priori as a possible 
confounder for pain outcomes.  
To be included in the study, baseline characteristics had to be provided by 
participants, resulting in limited missing baseline data. Missing data was assumed 
to be missing-at-random and was therefore ignored. Variables in which less than 
10% of the population contributed to one category were removed from the analysis. 
No veterans in this study were prescribed stimulant medication at baseline and 
therefore this was not included in the analysis. Sleep apnea was also not 
diagnosed among participants in this study at baseline and was not included in the 
analysis. Medication type and frequency of usage was provided by the participant 
in each of the assessment questionnaires. The following medication classes were 
included in the analysis: non-steroidal anti-inflammatory drugs (NSAIDs), opioids, 
over-the-counter pain medications (OTC), musculoskeletal relaxants, sleep aids 
(sedatives, hypnotics), anxiolytics, and anti-depressants. None of the medications 
were normally distributed at baseline and therefore were logged and then back 
transformed for interpretability. The following comorbid diagnosis were found at 
baseline and included in the analysis: hypertension (HTN), cancer, depression, 
anxiety, post-traumatic stress disorder (PTSD), chronic headaches, diabetes, 
metabolic syndrome, and chronic fatigue. These data were gathered from DAVMC 
medical records. 
A repeated measures mixed effects model (PROC MIXED in SAS) was 
used to evaluate the effects of group (HRVB vs. sham), time, and group by time 
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interaction. The following covariance matrices were considered: unstructured 
(UN), compound symmetric (CS), and heterogeneous compound symmetric (CSH) 
and the smallest Akaike Information Criterion (AIC) was selected for the final 
model. In the HRVB intervention group, one-tailed p-values were used for a priori 
directional hypotheses to determine the effectiveness of the HRVB intervention. 
Based on previous literature, the benefit of HRVB was expected to demonstrate 
positive effects and a directional change, therefore statistical significance was 
assessed utilizing one-tailed p-values to interpret results for specific comparisons 
in the intervention group. As there was no beneficial effect expected in the control 
group, the use of a priori directional hypotheses were not employed and were 
reported using two-tailed p-values. Pre-determined contrasts were made 
comparing Baseline Assessment with the Post-training Assessment, and Follow-
up Assessment. To assess treatment sustainability, the Post-training Assessment 
data were compared to the Follow-up Assessment. If baseline variables were 
statistically significantly different (p<0.05), then they were considered as possible 
confounders. Differing baseline demographic covariates were kept in the final 
model when the parameter estimates changed by ≥10%. This was applied until all 
statistically significant differing baseline covariates were checked. Statistically 
significant covariates were retained in the model without regard to the effect of the 
parameter estimate.  
HRV was compared between groups and assessments using least square 
(LS) means for the following HRV measures: SDNN, RMSSD, VLF power, LF 
power, HF power, and HRV Coherence Ratio. Normality was checked using PROC 
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UNIVARIATE. As the HRV variables were not normally distributed at baseline, 
each variable was logged and then back transformed for interpretability. HRV 
Coherence Ratio was calculated as previously cited by McCraty.7 In the linear 
mixed model, with group, time, group by time interaction, the best (lowest) AIC was 
found using the unstructured (UN) matrix. For the SDNN and RMSSD outcome, 
the same linear mixed model was used using the heterogeneous compound 
symmetry (CSH) covariance matrix as it provided the best AIC. For the VLF 
outcome, the same linear mixed model was used using the UN matrix. And for the 
LF and HF outcomes, the same linear mixed model was used using compound 
symmetry (CS) matrix. Results were back-transformed from the logged LS Means 
Estimates. 
 Outcomes for all pain variables (PS, PIS, and PCS) were reported using 
LS Means Estimates using the already described linear mixed model above. The 
PS outcome was reported using the CSH covariance matrix as it provided the best 
AIC while adjusting for depression and race. The PIS outcome was reported using 
the CSH covariance matrix as it provided the best AIC while adjusting for pain 
interference as PIS was different between groups at baseline. PCS outcome was 
reported using the CS covariance matrix as it provided the best AIC while adjusting 
for depression.  
The following pain medication variables were assessed: NSAIDs (i.e. 
piroxicam, meloxicam), opioids (i.e. morphine, oxycodone), OTC (i.e. aspirin, BC 
powder), musculoskeletal relaxants (i.e. cyclobenzaprine, methocarbamol), sleep 
aids (i.e. zolpidem, eszopiclone), anxiolytics (i.e. diazepam, alprazolam), and anti-
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depressants (i.e. fluoxetine, paroxetine). None of the pain medication was normally 
distributed at baseline when assessing using Proc Univariate. All reported 
medications were log transformed and then back-transformed for interpretability 
using the same linear mixed model already described. All medication results were 
reported as the back-transformed logged LS Means Estimates. NSAID outcomes 
were found to have the best AIC using the CSH covariance matrix. Opioid, OTC, 
sedatives, musculoskeletal, sleep, and anti-anxiety medications were found to 
have the best AIC using the CS covariance matrix. Anti-depressant medication 
outcomes were found to have the best AIC using the UN covariance matrix. 
For cognitive outcomes, PASAT and HVLT were assessed using the same 
linear mixed model, reported as LS Means Estimates, and were found to have the 
best AIC using the CS matrix while adjusting for race.  For the PVT cognitive 
outcomes (reaction time and lapses), in a review of literature, due to wide ranging 
results with the mean or median reaction time, multiple authors have 
recommended using the reciprocal of the mean reaction time.207-209 Emphasis was 
placed on the reciprocal of the mean reaction time. Outcomes of the reciprocal 
mean reaction time were assessed utilizing the same linear mixed models as 
described above with LS Means Estimates. The best AIC was found using the CSH 
covariance matrix while adjusting for race and then back-transformed for 
interpretability. As the number of lapses were not normally distributed, the number 
of lapses were log transformed using LS Means Estimates and then back-
transformed for interpretability. The best AIC was found using the UN covariance 
matrix while adjusting for race. 
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Depression (BDI) outcome was analyzed using the already established 
linear mixed model and reported using LS Means Estimates. The best AIC was 
found using the CS covariance matrix while adjusting for baseline depression as 
they were different between groups at baseline. Stress (PSS) outcome was 
reported using LS Means Estimates and the best AIC was found using the CSH 
covariance matrix while adjusting for race and depression. Fatigue (MFI) outcomes 
were reported using the five subcomponents of fatigue using LS Means Estimates 
from the already described linear mixed model. General fatigue was reported with 
the best AIC found using the CS covariance matrix while adjusting for race. Mental 
fatigue was found to have the best AIC with the CS matrix while adjusting for 
depression. Physical fatigue was found to have the best AIC using the CS matrix 
while adjusting for race. Reduced activity was found to have the best AIC using 
the CS matrix while adjusting for race and pain. Reduced motivation was found to 
have the best AIC using the CS matrix while adjusting for pain. 
 To test the effect size of the change in outcome measurements between 
Baseline to Post-training Assessment and Baseline to Follow-up Assessment, 
Cohen’s D was calculated using the following formula: Cohen’s D = (M2-
M1)/SDpooled.  
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CHAPTER 4 
RESULTS 
4.1 Overall Characteristic Results 
 A total of 85 United States military veterans were enrolled in the study, 63 
completed the Post-training Assessment, 54 achieved the Booster Assessment, 
and 50 accomplished the Follow-up Assessment (59% completion). Attrition by 
intervention group demonstrated no statistically significant differences (Figure A.4, 
Consort Flow Diagram). Demographic (Table 4.1) and comorbid variables (Table 
4.2) at baseline are displayed. Most demographic characteristics were equally 
proportioned. Participants were mostly male (66%), college educated (73%), and 
non-smokers (85%) (Table 4.1). Age was similar between groups; the average age 
(± standard error of the mean) for the HRVB intervention group was 54 ± 11 years 
and was 55 ± 12 in the control group. Race was the only baseline characteristic 
that exhibited statistically significant differences between groups (Caucasian: 37% 
in intervention vs 63% in control group, p=0.04, Table 4.1). Race was viewed as a 
potential confounder and considered as such in the statistical analyses. The 
amount of time it took for participants to complete this study due to cancellation of 
appointments or rescheduling was evaluated within both groups. 
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With no missed appointments or rescheduling, the study should have been 
completed in 112 days. Completion of the study protocol took on average 123 ± 
21 days and no statistically significant differences were observed between groups 
among protocol completers (124 days for intervention group, 121 days for control 
group, p=0.54, Table 4.1).  Evaluation of medical records at baseline was 
conducted of comorbid diagnoses as possible confounders (Table 4.2) however 
there were no statistically significant differences in comorbid diseases between the 
groups. Baseline scores for pain interference, depression (BDI), and race were 
statistically significantly different between groups. Further analysis was conducted 
among those who completed the study relative to those who were lost-to-follow-up 
(LTF). Of the 85 participants in the study, 9 were still active at the time of this 
analysis, 50 completed the study, and 26 were LTF. The 9 active participants were 
removed from completion status analysis. Among those who completed the study, 
the average age in years was 57±9.9 compared to those who were LTF were 
50±11.6 (p=0.01, Table 4.14). No other differences in demographics or 
comorbidities were found between those who completed the study and those who 
were LTF. 
4.2 HRV Results 
Least Square Means (LS Means) HRV Coherence Ratios increased 
between baseline and post-training within the intervention group (0.17 ± 0.02 at 
baseline versus 0.41 ± 0.07 at post-training, p=<0.01, Table 4.3) and between 
post-training and follow-up with in the intervention group (0.41 ± 0.07 at post-
training versus 0.45 ± 0.08 at follow-up, p=<0.03). The control group did not exhibit 
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any improvement between baseline and post-training (0.17 at baseline versus 0.18 
post-training, p=0.61) nor post-training to follow-up (0.18 at post-training versus 
0.18 at follow-up, p=0.94). Statistical significance was found in the group by 
timepoint interaction for the HRV Coherence Ratio (p=<0.01). LS Means HRV 
Coherence Ratios in the intervention group also were elevated at follow-up relative 
to baseline (0.17 ± 0.02 at baseline versus 0.45 ± 0.08 at follow-up, p=<0.01, Table 
4.4). Figure 4.1 displays the HRV Coherence Ratio for each of the timepoints. 
 LS Means SDNN was found to increase in both groups between baseline 
and post-training and only in the control group between baseline and follow-up. 
RMSSD and VLF increased only in the control group between baseline and post-
training (Tables 4.3 and 4.4). LF increased in both groups when comparing post-
training and follow-up to baseline (Figure 4.2) (Tables 4.3 and 4.4).  HF increased 
in the control group from baseline to post-training (Tables 4.3 and 4.4). 
4.3 Pain Results 
 Decreases in PS were observed among the intervention group while 
adjusting for race and depression with a reduction at post-training as compared to 
baseline (5.67 ± 0.25 at baseline versus 5.24 ± 0.27 at post-training, p=0.023, 
Table 4.5) and decreases were also observed between Baseline and Follow-up 
Assessment (5.67 ± 0.25 at baseline versus 5.13 ± 0.31 at follow-up, p=0.03, Table 
4.6). The group by time interaction also revealed statistically significant findings, 
p=0.04 (Tables 4.5 and 4.6) and displayed in Figure 4.3. 
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Baseline scores for pain interference were statistically significantly different 
between groups. Decreases in PIS were observed among the intervention group 
while adjusting for pain at baseline with a reduction at post-training as compared 
to baseline (5.67 ± 0.19 at baseline versus 4.74 ± 0.24 at post-training, p=<0.01, 
Table 4.5) and decreases were also observed between Baseline and Follow-up 
Assessment (5.67 ± 0.19 at baseline versus 4.69 ± 0.37 at follow-up, p=<0.01, 
Table 4.6). The group by time interaction also revealed statistically significant 
findings (p=<0.01, Tables 4.5 and 4.6, Figure 4.4).   
Decreases for PCS while adjusting for baseline depression were found in 
both groups from baseline to post-training and baseline follow-up: intervention 
group (25.56 ± 1.64 at baseline versus  at post-training 22.69 ± 1.8, p=0.01 , Table 
4.5) and (25.56 ± 1.64 at baseline versus at follow-up 21.00± 1.84, p=<0.01, Table 
4.6) whereas for the control group (28.06 ± 1.71 at baseline versus 24.44 ± 1.80 
at post-training , p=<0.01 , Table 4.5) and (28.06 ± 1.71 at baseline versus 23.87 
± 1.88 at follow-up, p=<0.01, Table 4.6)  However, there was not a statistically 
significant group by time interaction observed (p=0.58, Table 4.6) and displayed in 
Figure 4.5.  
Reductions in pain medication use were found in NSAIDS for the 
Intervention group at baseline compared to follow-up and reported in log back-
transformed LS Means Estimates (1.35 ± 0.10 at baseline versus 1.12 ± 0.10 at 
follow-up, p=0.02, Tables 4.7 and 4.8) however was not observed in the group by 
time interaction (p=0.08, Table 4.8). Results for NSAID use are displayed in Figure 
4.6 and for opioid use in Figure 4.7. 
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4.4 Cognitive Results 
 Increases for PASAT score after adjusting for race at baseline were seen in 
both groups between baseline and follow-up: intervention group (16.9 ± 1.09 at 
baseline versus 20.29 ± 1.21 at follow-up, p=<0.01, Table 4.10) and control group 
(18.52 ± 1.07 at baseline versus 21.06 ± 1.14 at follow-up, p=0.01, Table 4.10). 
There was not a statistically significant group by time interaction observed (p=0.16, 
Table 4.10). PASAT is displayed in Figure 4.8. 
Increases for HVLT after adjusting for race at baseline were seen in both 
groups between baseline and follow-up: intervention group (23.82 ± 0.79 at 
baseline versus 26.19 ± 0.93 at follow-up, p=<0.01, Table 4.10) and control group 
(23.92 ± 0.78 at baseline versus 26.84 ± 0.86 at follow-up, p=<0.01, Table 4.10). 
However, there was not a statistically significant group by time interaction 
observed (p=0.89, Table 4.10). HVLT is displayed in Figure 4.9. 
Decrease in the back-transformed reciprocal mean reaction time while 
adjusting for race at baseline was observed in the intervention group between 
baseline and follow-up (431.59± 17.32 at baseline versus 407.50 ± 17.71 at follow-
up, p=0.04, Table 4.10). However, there was not a statistically significant group by 
time interaction observed (p=0.90, Table 4.10). Reaction time is displayed in 
Figure 4.10. 
Decrease in the back-transformed logged number of lapses while adjusting 
for race at baseline were seen in both groups between baseline and follow-up: 
intervention group (9.056 ± 1.16 at baseline versus 6.05 ± 1.19 at follow-up, 
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p=<0.01, Table 4.10) and control group (9.054 ± 1.16 at baseline versus 6.46 ± 
1.18 at follow-up, p=0.01, Table 4.10). However, there was not a statistically 
significant group by time interaction observed (p=0.79, Table 4.10). Number of 
lapses is displayed in Figure 4.11. 
4.5 Depression, Stress, and Fatigue Results 
Baseline scores for depression (BDI) were statistically significantly different 
between groups. Decrease in the BDI while adjusting for depression at baseline 
was found in the intervention group from baseline and post-training (21.9 ± 1.04 at 
baseline versus 17.66 ± 1.22 at post-training, p=<0.01, Table 4.11) and baseline 
to follow-up (21.9 ± 1.04 at baseline versus 16.30 ± 1.34 at follow-up, p=<0.01, 
Table 4.12). There was a statistically significant group by time interaction observed 
(p=0.03, Table 4.12). BDI is displayed in Figure 4.12. 
 PSS did not result in any statistically significant results while adjusting for 
baseline depression for either group when comparing baseline to post-training and 
when comparing baseline to follow-up (Tables 4.11 and 4.12). There was no 
statistically significant group by time interaction observed (p=0.76, 4.12). PSS is 
displayed in Figure 4.13. 
 Adjustments were made for the five categories of fatigue: General fatigue 
was adjusted for baseline race, mental fatigue was adjusted for baseline 
depression, physical fatigue was adjusted for baseline race, reduced activity was 
adjusted for baseline race and pain, and reduced motivation was adjusted for 
baseline pain. Among all of these, there were no statistically significant 
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improvements for either group and no statistically significant group by time 
interactions. However, for the control group, there was a reported worsening of 
symptoms in physical fatigue with an increase from baseline to post-training (12.42 
± 0.31 at baseline versus 13.39 ± 0.35 at post-training, p=0.02, Table 4.11). 
General fatigue (Figure 4.14), mental fatigue (Figure 4.15), physical fatigue (Figure 
4.16), reduced activity (Figure 4.17), and reduced motivation (Figure 4.18) are 
displayed. 
 Post-hoc analysis was conducted as concern for possible over-adjusting of 
baseline differences of dependent variable outcomes. For example, both 
depression and pain interference differed at baseline and were originally adjusted 
in the linear mixed models. When using the CSH matrix, pain interference was 
reanalyzed using a linear mixed model without adjusting for baseline differences. 
In the intervention group, comparing baseline to post-training (6.95 ± 0.35 at 
baseline vs 6.05 ± 0.40 post-training, p=<0.01) and baseline to follow-up (6.95 ± 
0.35 at baseline vs 5.95 ± 0.46, p=<0.01) and in the control group comparing 
baseline to post-training (5.95 ± 0.36 at baseline vs 5.69 ± 0.40 post-training, 
p=0.39) and baseline to follow-up (5.95 ± 0.36  at baseline vs 5.76 ± 0.46, p=0.58).  
 Further analyses were performed for unadjusted depression using a CS 
matrix and a linear mixed model without adjusting for baseline differences. In the 
intervention group comparing baseline to post-training (23.95 ± 1.91 at baseline vs 
20.09 ± 2.05 post-training, p=<0.01) and baseline to follow-up (23.95 ± 1.91 at 
baseline vs 18.59 ± 2.13 at follow-up, p=<0.01) and in the control group comparing 
baseline to post-training (18.41 ± 1.97 at baseline vs 18.20 ± 2.07 post-training, 
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p=0.88) and baseline to follow-up (18.41 ± 1.97 at baseline vs 17.35 ± 2.17, 
p=0.49). 
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Table 4.1. Demographics 
 Total (n=85) HRVB (n=44) Control 
(n=41) 
p-value 
Age (years± SD) 54 ± 11 54 ± 11 55 ± 12 0.65 
Gender      n (%)    0.57 
F (%) 28 (33) 15(34)  13 (32)  
M (%) 56(66) 29 (66) 27 (66)  
Race    0.04 
Minorities (%) 53 (62) 32 (73) 21 (51)  
Caucasian (%) 32 (38) 12 (27) 20 (49)  
Education    0.65 
Less Than 
College 
23 (27) 10 (23) 13 (32)  
College 51 (60) 28 (63) 23 (56)  
Graduate 
School 
11 (13) 6 (14) 5 (12)  
Income    0.66 
Under $30,000 33 (39) 15 (34) 18 (44)  
$30,000-50,000 17 (20) 8 (18) 9 (22)  
$50,001 or more 30 (35) 18 (41) 12 (29)  
Refused 4 (5) 2 (5) 2 (5)  
Don’t know 1 (1) 1 (2) 0 (0)  
Current Smoke     
Yes 13 (15) 6 (14) 7 (17) 0.66 
No 72 (85) 38 (86) 34 (83)  
Smoke 
Cigarette Ever 
   0.63 
Yes 35 (41) 18 (41) 17 (41)  
No 45 (53) 24 (55) 21 (51)  
Don’t Know 1 (1) 1 (2) 0 (0)  
Missing 4 1 (2) 2  
Study 
Completion in 
Days ± SD  
123 ± 21 124 ± 18 121 ± 23 0.54 
 
Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for 
categorical variables.  Pooled T-test used for continuous variables. F: Female. M: 
Male. SD: Standard Deviation.  Study Completion in Days: Total days to complete 
study from Baseline visit to completion of Follow-up Assessment.  
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Table 4.2. Comorbidities at Baseline by Group 
 
 Overall 
(n=85) 
Intervention 
(n=44) 
Control 
(n=41) 
p-value 
Hypertension    0.38 
Yes (%) 38 (45) 22 (50) 16 (39)  
No (%) 47 (55) 22 (50) 25 (61)  
Cancer    0.92 
Yes (%) 8 (9) 4 (9) 4 (10)  
No (%) 77 (91) 40 (91) 37 (90)  
Depression    0.91 
Yes (%) 42 (49) 22 (50) 20 (49)  
No (%) 43 (51) 22 (50) 21 (51)  
Anxiety    0.26 
Yes (%) 19 (22) 12 (27) 7 (17)  
No (%) 66 (78) 32 (73) 34 (83)  
PTSD    0.98 
Yes (%) 31 (36) 16 (36) 15 (37)  
No (%) 54 (64) 28 (64) 26 (63)  
Diabetes    0.45 
Yes (%) 24 (28) 14 (32) 10 (24)  
No (%) 61 (72) 30 (68) 31 (76)  
 
Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for 
categorical variables.  Pooled T-test used for continuous variables. F: Female. M: 
Male. SD: Standard Deviation.  Study Completion in Days: Total days to complete 
study from Baseline visit to completion of Follow-up Assessment. PTSD: Post 
Traumatic Stress Disorder.  
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Table 4.3: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Post-training Assessments 
 
Outcome Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
HRV Coherence 
Ratio 
 
A 
 
0.17 ± 0.02 
 
43 
 
0.41 ± 0.07 
 
31 
0.24 ± 0.08 
(4.59, <0.01c) 
 
(20.27, <0.01) 
 
B 
 
0.17 ± 0.02 
 
41 
 
0.18 ± 0.03 
 
32 
0.01 ± 0.17 
(0.51, 0.61d) 
 
(6.62, <0.01) 
Est A-B±SE 
(t, p) 
0.01 ± 0.16 
(0.22, 0.82a) 
 
84 
0.23 ± 0.11 
(3.30, <0.01b) 
 
63 
 
n/a 
 
(5.95, <0.01) 
 
SDNN 
 
 
A 
 
27.5 ± 2.22 
 
43 
 
31.7 ± 3.24 
 
31 
4.2 ± 0.08 
(-1.63, 0.05c) 
 
(0.45, 0.51) 
 
B 
 
27.9 ± 2.31 
 
41 
 
37.6 ± 3.84 
 
32 
9.7 ± 0.06 
(-3.40, <0.01d) 
 
(4.88, <0.01) 
Est A-B±SE 
(t, p) 
-0.4 ± 0.1 
(0.13, 0.89a) 
 
84 
-5.9 ± 0.17 
(-1.18, 0.12b) 
 
63 
 
n/a 
 
(0.61, 0.61) 
 
 
A 
 
16.9 ± 1.74  
 
43 
 
17.2 ± 2.32 
 
31 
0.3 ± 0.11 
(-0.18, 0.43c) 
 
(0.68, 0.41) 
RMSSD 
 
B 
 
16.7 ± 1.76 
 
41 
 
23.4 ± 3.16 
 
32 
6.7 ± 0.08 
(-2.96, <0.01d) 
 
(1.75, 0.16) 
 
Est A-B±SE 
(t, p) 
0.2 ± 0.11 
(-0.07, 0.94a) 
 
84 
-6.2 ± 0.26 
(1.61, 0.05b) 
 
63 
 
n/a 
 
(1.51, 0.21) 
 
 
A 
 
265.0 ± 46.7 
 
43 
 
230.0 ± 46.6 
 
31 
-35.0 ± 0.24 
(0.66, 0.25c) 
 
(4.65, 0.03) 
VLF Power 
 
B 
 
259.0 ± 46.9  
 
41 
 
429.0 ± 86.2 
 
32 
170.0 ± 0.12 
(-2.46, 0.02d) 
 
(0.86,0.46) 
 
Est A-B±SE 
(t, p) 
6.0 ± 0.25 
(-0.08, 0.94a) 
 
84 
-199.0 ± 0.52 
(-2.18, 0.02b) 
 
63 
 
n/a 
 
(4.48, <0.01) 
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LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence SDNN: Standard Deviation of 
the Normal to Normal in milliseconds (ms). RMSSD: Root Mean Square of the Successive Differences in ms. VLF Power: 
Very Low Frequency Power in ms2. LF Power: Low Frequency Power in ms2. HF Power: High Frequency Power in ms2. 
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment 
and Post-training Assessment. d2-sided comparison between Baseline Assessment and Post-training Assessment. µ: 
Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: test statistic. p: p-value. Group x Timepoint: 
Type 3 test of fixed effects for group by timepoint interaction term (1-sided).        
  
Table 4.3: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Post-training Assessments 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
LF Power 
 
 
A 
 
167.6 ± 36.8 
 
43 
 
442.5 ± 106 
 
31 
274.9 ± 0.08 
(-4.34, <0.01c) 
 
(1.05, 0.31) 
 
B 
 
170.3 ± 37.3 
 
41 
 
309.4 ± 74 
 
32 
139.1 ± 0.12 
(-2.69, <0.01d) 
 
(11.36, <0.01) 
Est A-B±SE 
(t, p) 
-2.7 ± 0.31 
(-0.05, 0.96a) 
 
84 
133.1 ± 0.24 
(-1.06, 0.29b) 
 
63 
 
n/a 
 
(0.77, 0.51) 
HF Power 
 
A 
 
81.1 ± 18.8 
 
43 
 
70.4 ± 17.8 
 
31 
-10.7 ± 0.27 
(0.61, 0.27c) 
 
(1.61, 0.21) 
 
B 
 
85.1 ± 20.2 
 
41 
 
155.9 ± 40.1 
 
32 
70.8 ± 0.13 
(-2.6, 0.01d) 
 
(0.74, 0.53) 
Est A-B±SE 
(t, p) 
-4.0 ± 0.35 
(0.15, 0.89a) 
 
84 
 
 
-85.5 ± 0.81 
(2.19, 0.02b) 
 
63 
 
 
n/a 
 
(1.93, 0.13) 
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Table 4.4: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Follow-up Assessments 
 
Outcome Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
HRV Coherence 
Ratio 
 
A 
 
0.17 ± 0.02 
 
43 
 
0.45 ± 0.08 
 
25 
0.28 ± 0.07 
(-5.25, <0.01c) 
 
(20.27, <0.01) 
 
B 
 
0.17 ± 0.02 
 
41 
 
0.19 ± 0.03 
 
25 
0.02 ± 0.16 
(-0.60, 0.55d) 
 
(6.62, <0.01) 
Est A-B±SE 
(t, p) 
0.01 ± 0.16 
(-0.22, 0.82a) 
 
84 
0.26 ± 0.10 
(-3.75, <0.01b) 
 
50 
 
n/a 
 
(5.95, <0.01) 
 
SDNN 
 
 
A 
 
27.5 ± 2.22 
 
43 
 
31.1 ± 3.79 
 
25 
3.6 ± 0.09 
(-1.18, 0.12c) 
 
(0.45, 0.51) 
 
B 
 
27.9 ± 2.31 
 
41 
 
34.8 ± 4.27 
 
25 
7 ± 0.08 
(-2.09, 0.04d) 
 
(4.88, <0.01) 
Est A-B±SE 
(t, p) 
-0.4 ± 0.1 
(0.13, 0.89a) 
 
84 
-3.7 ± 0.19 
(0.65, 0.26b) 
 
50 
 
n/a 
 
(0.61, 0.61) 
 
 
A 
 
16.9 ± 1.74  
 
43 
 
16.25 ± 1.93 
 
25 
-0.65 ± 0.11 
(0.36, 0.36c) 
 
(0.68, 0.41) 
RMSSD 
 
B 
 
16.7 ± 1.76 
 
41 
 
18.96 ± 2.27 
 
25 
2.26 ± 0.10 
(-1.13, 0.26d) 
 
(1.75, 0.16) 
 
Est A-B±SE 
(t, p) 
0.2 ± 0.11 
(-0.07, 0.94a) 
 
84 
-2.71 ± 0.20 
(0.91, 0.18b) 
 
50 
 
n/a 
 
(1.51, 0.21) 
 
 
A 
 
265.0 ± 46.7 
 
43 
 
210.0 ± 55.7 
 
25 
-54.0 ± 0.32 
(0.9, 0.18c) 
 
(4.65, 0.03) 
VLF Power 
 
B 
 
259.0 ± 46.9  
 
41 
 
408.0 ± 109 
 
25 
154.0 ± 0.16 
(-1.77, 0.08d) 
 
(0.86,0.46) 
 
Est A-B±SE 
(t, p) 
6.0 ± 0.25 
(-0.08, 0.94a) 
 
84 
-198.0 ± 0.73 
(1.77, 0.04b) 
 
50 
 
n/a 
 
(4.48, <0.01) 
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LS-Means estimates displayed as mean. Larger scores represent greater HRV Coherence SDNN: Standard Deviation of 
the Normal to Normal measured in milliseconds (ms). RMSSD: Root Mean Square of the Successive Differences in ms. 
VLF Power: Very Low Frequency Power in ms2. LF Power: Low Frequency Power in ms2. HF Power: High Frequency 
Power in ms2. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline 
Assessment and Follow-up Assessment. d2-sided comparison between Baseline Assessment and Follow-up Assessment. 
µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value. 
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided).        
  
Table 4.4: Mixed Model Analysis of HRV Outcomes Comparing Baseline vs. Follow-up Assessments 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-training (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
LF Power 
 
 
A 
 
167.6 ± 36.8 
 
43 
 
427.8 ± 109.8 
 
25 
260.2 ± 0.09 
(-3.88, <0.01c) 
 
(1.05, 0.31) 
 
B 
 
170.3 ± 37.3 
 
41 
 
279.2 ± 72.1 
 
25 
108.9 ± 0.15 
(-2.04, 0.04d) 
 
(11.36, <0.01) 
Est A-B±SE 
(t, p) 
-2.7 ± 0.31 
(-0.05, 0.96a) 
 
84 
148.6 ± 0.24 
(-1.17, 0.12b) 
 
50 
 
n/a 
 
(0.77, 0.51) 
 
HF Power 
A  
81.1 ± 18.8 
 
43 
 
68.1 ± 18.7 
 
25 
-13.0 ± 0.27 
(0.61, 0.27c) 
 
(1.61, 0.21) 
B  
85.1 ± 20.2 
 
41 
 
109.0 ± 30.1 
 
25 
23.9 ± 0.20 
(-0.97, 0.33) 
 
(0.74, 0.53) 
Est A-B±SE 
(t, p) 
-4.0 ± 0.35 
(0.15, 0.88a) 
 
84 
-40.9 ±0.62 
(1.21, 0.11b) 
 
50 
 
n/a 
 
(1.93, 0.13) 
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Table 4.5: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-Training Assessments 
 
Outcome Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
 
Pain Severity 
Score#  
 
A 
 
5.67 ± 0.25 
 
44 
 
5.24 ± 0.27 
 
31 
0.43 ± 0.21 
(2.02, 0.02c) 
  
(4.90, 0.03) 
 
B 
 
5.93 ± 0.25 
 
41 
 
5.72 ± 0.26 
 
32 
0.21 ± 0.21 
(0.99, 0.32d) 
 
(1.68, 0.18) 
Est A-B±SE   
(t, p) 
0.26 ± 0.36 
(0.73, 0.47a) 
 
85 
0.48 ± 0.38 
(1.27, 0.21a) 
 
63 
 
n/a 
 
(2.91, 0.04) 
Pain Interference 
Score^ 
 
A 
 
5.67 ± 0.19 
 
44 
 
4.74 ± 0.24 
 
31 
0.93 ± 0.26  
(3.53, <0.01c) 
  
(5.77, 0.02) 
 
B 
 
5.59 ± 0.18 
 
41 
 
5.33 ± 0.23 
 
32 
0.26 ± 0.26  
(0.98, 0.33d) 
 
(3.74, 0.01) 
Est A-B±SE  
(t, p) 
-0.08 ± 0.25   
(-0.31, 0.76a) 
 
85 
0.59 ± 0.33  
(1.81, 0.07a) 
 
63 
 
n/a 
 
(4.40, <0.01) 
 
Pain 
Catastrophizing 
Scale* 
 
 
A 
 
25.56 ± 1.6 
 
44 
 
 22.69 ± 1.8  
 
31 
2.87 ± 1.23  
(2.34, 0.01c) 
 
(1.55, 0.22) 
 
B 
 
28.06 ± 2  
 
41 
 
24.44 ± 1.8  
 
32 
3.62 ± 1.22  
(2.98, <0.01d) 
 
(9.52, <0.01) 
Est A-B±SE   
(t, p) 
2.49 ± 2.40  
(1.04, 0.30a) 
 
85 
1.75 ± 2.55  
(0.68, 0.49a) 
 
63 
 
n/a 
 
(0.66, 0.58) 
 
LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: 
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. #Adjusted for baseline race and depression.  
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LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline 
Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-
test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. #Adjusted for baseline race and depression.  
 
 
Table 4.6: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-Up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
 
Pain Severity 
Score#  
 
A 
 
5.67 ± 0.25 
 
44 
 
5.13 ± 0.31 
 
25 
-0.54 ± 0.28 
(1.89, 0.03c) 
  
(4.90, 0.03) 
 
B 
 
5.93 ± 0.25 
 
41 
 
6.04 ± 0.30 
 
25 
0.11 ± 0.28 
(-0.41, 0.68d) 
 
(1.68, 0.18) 
Est A-B±SE   
(t, p) 
-0.26 ± 0.36 
(0.73, 0.47a) 
 
85 
-0.91 ± 0.43 
(2.11, 0.037a) 
 
50 
 
n/a 
 
(2.91, 0.04) 
Pain Interference 
Score^ 
 
A 
 
5.67 ± 0.19 
 
44 
 
4.69 ± 0.37 
 
25 
-0.98 ± 0.37  
(2.65, <0.01c) 
  
(5.77, 0.02) 
 
B 
 
5.59 ± 0.18 
 
41 
 
5.40 ± 0.37 
 
25 
-0.19 ± 0.37  
(0.50, 0.62d) 
 
(3.74, 0.01) 
Est A-B±SE  
(t, p) 
-0.08 ± 0.25   
(-0.31, 0.76a) 
 
85 
-0.71 ± 0.52  
(1.38, 0.17a) 
 
50 
 
n/a 
 
(4.40, <0.01) 
 
 
A 
 
25.56 ± 1.64 
 
44 
 
 21.00 ± 1.84  
 
25 
-4.56 ± 1.33  
(3.44, <0.01c) 
 
(1.55, 0.22) 
Pain 
Catastrophizing 
Scale* 
 
B 
 
28.06 ± 1.71  
 
41 
 
23.87 ± 1.88  
 
25 
-4.19 ± 1.33  
(3.15, <0.01d) 
 
(9.52, <0.01) 
 
Est A-B±SE   
(t, p) 
-2.50 ± 2.40  
(1.04, 0.30a) 
 
85 
-2.87 ± 2.66  
(1.08, 0.28a) 
 
50 
 
n/a 
 
(0.66, 0.58) 
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Table 4.7: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-training Assessments 
 
Outcome Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Opioid 
 
A 
 
1.33 ± 0.11 
 
43 
 
1.42 ± 0.14 
 
31 
0.09 ± 0.09 
(0.64, 0.26c) 
 
(0.01, 0.92) 
 
B 
 
1.31 ± 0.35 
 
41 
 
1.35 ± 0.13 
 
32 
0.04 ± 0.11 
(0.41, 0.68d) 
 
(1.17, 0.32) 
Est A-B±SE 
(t, p) 
0.02 ± 0.11 
(0.17, 0.86a) 
 
84 
0.07 ± 0.13 
(0.34, 0.73b) 
 
63 
 
n/a 
 
(0.72, 0.54) 
 
Non-steroidal anti-
inflammatory drug 
 
 
A 
 
1.35 ± 0.10 
 
43 
 
1.21 ± 0.11 
 
31 
-0.14 ± 0.10 
(1.28, 0.10c) 
 
(2.43, 0.12) 
 
B 
 
1.32 ± 0.10 
 
41 
 
1.51 ± 0.14 
 
32 
0.19 ± 0.08 
(1.51, 0.13d) 
 
(2.16, 0.09) 
Est A-B±SE 
(t, p) 
0.03 ± 0.11 
(0.22, 0.83a) 
 
84 
-0.3 ± 0.16 
(1.77, 0.04b) 
 
63 
 
n/a 
 
(2.27, 0.08) 
 
 
A 
 
2.60 ± 0.33  
 
43 
 
2.43 ± 0.35 
 
31 
-0.17 ± 0.15 
(0.48, 0.32c) 
 
(0.09, 0.77) 
Over-the-counter 
 
B 
 
2.72 ± 0.36 
 
41 
 
2.25 ± 0.33 
 
32 
-0.47 ± 0.17 
(1.35, 0.18d) 
 
(0.89, 0.45) 
 
Est A-B±SE 
(t, p) 
-0.12 ± 0.19 
(0.24, 0.81a) 
 
84 
0.18 ± 0.17 
(1.35, 0.09b) 
 
63 
 
n/a 
 
(0.88, 0.45) 
 
 
A 
 
1.64 ± 0.15 
 
43 
 
1.80 ± 0.19 
 
31 
0.16 ± 0.2 
(-0.66, 0.26c) 
 
(1.77, 0.19) 
Musculoskeletal 
 
B 
 
1.47 ± 0.14  
 
41 
 
1.29 ± 0.13 
 
32 
-0.18 ± 0.1 
(2.42, <0.01d) 
 
(0.07, 0.98) 
 
Est A-B±SE 
(t, p) 
0.17 ± 0.12 
(0.84, 0.40a) 
 
84 
0.51 ± 0.11 
(2.28, 0.01b) 
 
63 
 
n/a 
 
(1.35,0.26) 
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Back-transformed logged LS-Means estimates of number of pills per day. a2-sided comparison between groups. b1-sided 
test between groups. c1-sided comparison between Baseline Assessment and Post-training Assessment. d2-sided 
comparison between Baseline Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: 
Timepoint 1. T2: Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects 
for group by timepoint interaction term (1-sided).   
Table 4.7: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Post-training Assessments 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
Sleep 
 
 
A 
 
1.15 ± 0.07 
 
43 
 
1.27 ± 0.09 
 
31 
0.12 ± 0.07 
(1.38, 0.08c) 
 
(0.03, 0.86) 
 
B 
 
1.19 ± 0.07 
 
41 
 
1.02 ± 0.07 
 
32 
-0.17 ± 0.08 
(0.14, 0.89d) 
 
(0.91, 0.44) 
Est A-B±SE 
(t, p) 
-0.04 ± 0.09 
(0.39, 0.70a) 
 
84 
0.25 ± 0.10 
(0.06, 0.48b) 
 
63 
 
n/a 
 
(0.07, 0.98) 
Anti-Anxiety 
 
A 
 
1.44 ± 0.15 
 
43 
 
1.63 ± 0.19 
 
31 
0.19 ± 0.08 
(1.29, 0.10c) 
 
(3.45, 0.07) 
 
B 
 
1.76 ± 0.19 
 
41 
 
1.94 ± 0.22 
 
32 
0.18 ± 0.08 
(1.06, 0.29d) 
 
(1.32, 0.27) 
Est A-B±SE 
(t, p) 
-0.32 ± 0.18 
(1.33, 0.18a) 
 
84 
-0.31 ± 0.20 
(1.09, 0.14b) 
 
63 
 
n/a 
 
(0.65, 0.59) 
 
 
A 
 
1.50 ± 0.12 
 
43 
 
1.48 ± 0.13 
 
31 
-0.02 ± 0.09 
(0.10, 0.46c) 
 
(0.28, 0.60) 
Anti-depressant 
 
B 
 
1.31 ± 0.11 
 
41 
 
1.28 ± 0.12 
 
32 
-0.03 ± 0.09 
(0.28, 0.78d) 
 
(0.15, 0.93) 
 
Est A-B±SE 
(t, p) 
0.19 ± 0.002 
(1.13, 0.26a) 
 
84 
0.20 ± 0.11 
(1.15, 0.13b) 
 
63 
 
n/a 
 
(1.37, 0.26) 
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Table 4.8: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-up Assessments 
 
Outcome Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Opioid 
 
A 
 
1.33 ± 0.11 
 
43 
 
1.30 ± 0.13 
 
25 
-0.03 ± 0.11 
(0.28, 0.39c) 
 
(0.01, 0.92) 
 
B 
 
1.31 ± 0.35 
 
41 
 
1.25 ± 0.13 
 
25 
-0.06 ± 0.11 
(0.41, 0.68d) 
 
(1.17, 0.32) 
Est A-B±SE 
(t, p) 
0.02 ± 0.11 
(0.17, 0.86a) 
 
84 
0.05 ± 0.15 
(0.24, <0.41b) 
 
50 
 
n/a 
 
(0.72, 0.54) 
 
Non-steroidal anti-
inflammatory 
drug 
 
 
A 
 
1.35 ± 0.10 
 
43 
 
1.12 ± 0.10 
 
25 
-0.23 ± 0.11 
(2.16, 0.02c) 
 
(2.43, 0.12) 
 
B 
 
1.32 ± 0.10 
 
41 
 
1.45 ± 0.12 
 
25 
0.13 ± 0.09 
(1.01, 0.31d) 
 
(2.16, 0.09) 
Est A-B±SE 
(t, p) 
0.03 ± 0.11 
(0.22, 0.83a) 
 
84 
-0.33 ± 0.2 
(-1.15, 0.13b) 
 
50 
 
n/a 
 
(2.27, 0.08) 
 
 
A 
 
2.60 ± 0.33 
 
43 
 
2.28 ± 0.36 
 
25 
-0.32 ± 0.17 
(0.87, 0.19c) 
 
(0.09, 0.77) 
Over-the-counter 
 
B 
 
2.72 ± 0.36 
 
41 
 
2.47 ± 0.39 
 
25 
-0.25 ± 0.17 
(0.64, 0.53d) 
 
(0.89, 0.45) 
 
Est A-B±SE 
(t, p) 
-0.12 ± 0.19 
(0.24, 0.81a) 
 
84 
-0.19 ± 0.24 
(0.36, 0.36b) 
 
50 
 
n/a 
 
(0.88, 0.45) 
 
 
A 
 
1.64 ± 0.15 
 
43 
 
1.62 ± 0.18 
 
25 
-0.02 ± 0.11 
(0.12, 0.45c) 
 
(1.77, 0.19) 
Musculoskeletal 
 
B 
 
1.47 ± 0.14  
 
41 
 
1.46 ± 0.16 
 
25 
-0.01 ± 0.11 
(0.02, 0.98d) 
 
(0.07, 0.98) 
 
Est A-B±SE 
(t, p) 
0.17 ± 0.12 
(0.84, 0.40a) 
 
84 
0.16 ± 014 
(0.64, 0.26b) 
 
50 
 
n/a 
 
(1.37, 0.26) 
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Back-transformed logged LS-Means estimates of number of pills per day. a2-sided comparison between groups. b1-sided 
test between groups. c1-sided comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison 
between Baseline Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: 
Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by 
timepoint interaction term (1-sided).  
 
Table 4.8: Mixed Model Analysis of Pain Outcomes Comparing Baseline vs. Follow-up Assessments 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Sleep 
 
 
A 
 
1.15 ± 0.07 
 
43 
 
1.17 ± 0.09 
 
25 
0.02 ± 0.08 
(0.26, 0.40c) 
 
(0.03, 0.86) 
 
B 
 
1.19 ± 0.07 
 
41 
 
1.20 ± 0.09 
 
25 
0.01 ± 0.08 
(0.14, 0.89d) 
 
(0.91, 0.44) 
Est A-B±SE 
(t, p) 
-0.04 ± 0.09 
(0.39, 0.70a) 
 
84 
-0.03 ± 011 
(0.23, 0.41b) 
 
50 
 
n/a 
(0.07, 0.98) 
 
Anti-anxiety 
 
A 
 
1.44 ± 0.15 
 
43 
 
1.35 ± 0.16 
 
25 
-0.09 ± 0.11 
(0.65, 0.26c) 
 
(3.45, 0.07) 
 
B 
 
1.76 ± 0.19 
 
41 
 
1.84 ± 0.23 
 
25 
0.08 ± 0.10 
(0.44, 0.66d) 
 
(1.32, 0.27) 
Est A-B±SE 
(t, p) 
-0.32 ± 0.18 
(1.33, 0.18a)) 
 
84 
-0.49 ±0.24 
(1.81, 0.07) 
 
50 
 
n/a 
 
(0.65, 0.59) 
 
 
A 
 
1.50 ± 0.12 
 
43 
 
1.33 ± 0.14 
 
25 
-0.17 ± 0.12 
(1.12, 0.13c) 
 
(0.28, 0.60) 
Anti-depressant 
 
B 
 
1.31 ± 0.11 
 
41 
 
1.47 ± 0.15 
 
25 
0.16 ± 0.10 
(1.01, 0.31d) 
 
(0.15, 0.93) 
 
Est A-B±SE 
(t, p) 
0.19 ± 0.002 
(1.13, 0.26a) 
 
84 
-0.14 ± 0.16 
(0.70, 0.48b) 
 
50 
 
n/a 
 
(1.37, 0.26) 
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Table 4.9: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Post-Training Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
PASAT+ 
 
A 
 
16.9 ± 1.09 
 
44 
 
18.04 ± 1.19 
 
31 
1.14 ± 0.91 
(-1.25, 0.11c) 
  
(0.22, 0.64) 
 
B 
 
18.52 ± 1.07 
 
41 
 
17.37 ± 1.14 
 
32 
-1.15 ± 0.90 
(1.28, 0.20d) 
 
(11.75, <0.01) 
Est A-B±SE  
(t, p) 
-1.62 ± 1.53 
(1.06, 0.29a)  
 
85 
0.67 ± 1.65 
(-0.4, 0.69a) 
 
63 
 
n/a 
 
(1.90, 0.16)  
HVLT+ 
 
 
A 
 
23.82 ± 0.79 
 
44 
 
24.99 ± 0.90 
 
31 
1.17 ± 0.84 
(-1.39, 0.09c) 
  
(0.10, <0.75) 
 
B 
 
23.92 ± 0.78 
 
41 
 
25.16 ± 0.86 
 
32 
1.24 ± 0.83 
(-1.50, 0.14d) 
 
(8.84, <0.01) 
Est A-B±SE   
(t, p) 
-0.10 ± 1.11 
(0.09, 0.93a) 
 
85 
-0.17 ± 1.24 
(0.14, 0.89a) 
 
63 
 
n/a 
 
(0.12, 0.89) 
 
LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: 
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for 
baseline race and depression. § Adjusted for baseline race and pain. 
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Table 4.9: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Post-Training Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Mean Reaction 
Time+ 
 
A 
 
431.59 ± 17.32 
 
 
44 
 
416.32 ± 17.85 
 
 
31 
-15.27 ± 0.53 
(-1.15, 0.13c) 
  
(0.04, 0.84) 
 
B 
 
431.22 ± 16.74 
 
 
41 
 
423.37 ± 17.39 
 
 
31 
-7.85 ± 0.65  
(-0.60, 0.55d) 
 
(2.37, 0.11) 
Est A-B±SE  
(t, p) 
0.37 ± 0.58   
(0.01, 0.99a) 
 
85 
-7.05 ± 0.46  
(-0.28, 0.78a) 
 
62 
 
n/a 
 
(0.11, 0.90) 
  
Lapses+ 
 
 
A 
 
9.056 ± 1.164 
 
43 
 
 8.04 ± 1.18  
 
31 
-1.016 ± 0.016  
(1.00, 0.16c) 
 
(0.03, 0.85) 
 
B 
 
9.054 ± 1.161  
 
41 
 
8.004 ± 1.17  
 
31 
-1.05 ± 0.009  
(1.46, 0.15d) 
 
(9.19, <0.01) 
Est A-B±SE   
(t, p) 
0.002 ± 0.003  
(0.24, 0.81a) 
 
84 
0.036 ± 0.01 
(-0.02, 0.98a) 
 
62 
 
n/a 
 
(0.23, 0.79) 
 
Reaction time LS-Means estimates displayed in milliseconds (ms). Back-transformed logged number of lapses displayed. 
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment 
and Post-training Assessment. d2-sided comparison between Baseline Assessment and Post-training Assessment. µ: 
Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value. 
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline 
depression.   ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. § 
Adjusted for baseline race and pain.  
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Table 4.10: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
PASAT+ 
 
A 
 
16.9 ± 1.09 
 
44 
 
20.29 ± 1.21 
 
25 
3.39 ± 0.94 
(-3.60, <0.01c) 
  
(0.22, 0.64) 
 
B 
 
18.52 ± 1.07 
 
41 
 
21.06 ± 1.14 
 
25 
2.54 ± 0.94 
(-2.51, 0.01d) 
 
(11.75, <0.01) 
Est A-B±SE  
(t, p) 
-1.62 ± 1.53 
(1.06, 0.29a)  
 
85 
-0.77 ± 1.68 
(0.46, 0.65a) 
 
50 
 
n/a 
 
(1.90, 0.16)  
HVLT+ 
 
 
A 
 
23.82 ± 0.79 
 
44 
 
26.19 ± 0.93 
 
25 
2.37 ± 0.88 
(-2.69, <0.01c) 
  
(0.10, <0.75) 
 
B 
 
23.92 ± 0.78 
 
41 
 
26.84 ± 0.86 
 
25 
2.92 ± 0.88 
(-3.21, <0.01d) 
 
(8.84, <0.01) 
Est A-B±SE   
(t, p) 
-0.10 ± 1.11 
(0.09, 0.93a) 
 
85 
-0.65 ± 1.29 
(0.51, 0.61a) 
 
50 
 
n/a 
 
(0.12, 0.89) 
 
LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline 
Assessment and Follow-up Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-
test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for 
baseline race and depression. § Adjusted for baseline race and pain.  
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Table 4.10: Mixed Model Analysis of Cognitive Variables Comparing Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
Mean Reaction 
Time+ 
 
A 
 
431.59 ± 17.32 
 
 
44 
 
407.50 ± 17.71 
 
 
25 
-24.09 ± 0.39 
(-1.78, 0.04c) 
  
(0.04, 0.84) 
 
B 
 
431.22 ± 16.74 
 
 
41 
 
413.91 ± 17.82 
 
 
25 
-17.31 ± 1.08  
(-1.26, 0.22d) 
 
(2.37, 0.11) 
Est A-B±SE  
(t, p) 
0.37 ± 0.58   
(0.01, 0.99a) 
 
85 
-6.41± 0.11  
(-0.26, 0.80a) 
 
50 
 
n/a 
 
(0.11, 0.90) 
Lapses+ 
 
A 
 
9.056 ± 1.164 
 
43 
 
 6.05 ± 1.19  
 
25 
-3.006 ± 0.026  
(2.71, <0.01c) 
 
(0.03, 0.85) 
 
B 
 
9.054 ± 1.161  
 
41 
 
6.46 ± 1.18  
 
25 
0.39 ± 0.16  
(2.50, 0.01d) 
 
(9.19, <0.01) 
Est A-B±SE   
(t, p) 
0.002 ± 0.003  
(0.24, 0.81a) 
 
84 
-0.41 ± 0.01 
(0.28, 0.78a) 
 
50 
 
n/a 
 
(0.23, 0.79) 
 
Reaction time LS-Means estimates displayed in milliseconds (ms). Back-transformed logged number of lapses displayed. 
a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison between Baseline Assessment 
and follow-up. d2-sided comparison between Baseline Assessment and Follow-up Assessment. µ: Mean. SE: Standard 
error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 
3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline depression.   ^Adjusted for 
baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. § Adjusted for baseline race and 
pain.  
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Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
BDI Score* 
 
A 
 
21.9 ± 1.04 
 
44 
 
17.66 ± 1.22 
 
31 
-4.24 ± 1.35 
(3.14, <0.01c) 
  
(3.54, 0.06) 
 
B 
 
21.1 ± 1.08 
 
41 
 
20.97 ± 1.21 
 
32 
-0.13 ± 1.35 
(0.1, 0.92d) 
 
(5.73, <0.01) 
Est A-B±SE  
(t, p) 
0.8 ± 1.5 
(-0.52, 0.6a)  
 
85 
-3.31 ± 1.7 
(1.92, 0.057a) 
 
63 
 
n/a 
 
(2.42, 0.03)  
Perceived 
Stress Score* 
 
A 
 
22.46 ± 0.66 
 
44 
 
21.72 ± 0.76 
 
31 
-0.74 ± 0.77 
(0.96, 0.17c) 
  
(1.66, 0.20) 
 
B 
 
23.76 ± 0.69 
 
41 
 
22.26 ± 0.76 
 
32 
-1.50 ± 0.76 
(1.96, 0.05d) 
 
(2.83, 0.04) 
Est A-B±SE   
(t, p) 
-1.30 ± 0.96 
(1.35, 0.18a) 
 
85 
-0.54 ± 1.09 
(0.5, 0.62a) 
 
63 
 
n/a 
 
(0.38, 0.76) 
General 
Fatigue+ 
 
 
A 
 
12.51 ± 0.36 
 
44 
 
11.92 ± 0.42 
 
31 
-0.59 ± 0.43  
(1.36, 0.09c) 
  
(0.00, 0.97) 
 
B 
 
12.38 ± 0.36 
 
41 
 
12.37 ± 0.40 
 
31 
-0.01 ± 0.43  
(0.04, 0.97d) 
 
(2.48, 0.06) 
Est A-B±SE  
(t, p) 
0.13 ± 0.5   
(-0.25, 0.80a) 
 
85 
-0.45 ± 0.58  
(0.77, 0.44a) 
 
62 
 
n/a 
 
(0.45, 0.72) 
 
LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. 
t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint 
interaction term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. +Adjusted for baseline race. 
#Adjusted for baseline race and depression. § Adjusted for baseline race and pain.  
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Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint 
(f, p) 
Mental Fatigue* 
 
 
A 
 
11.08 ± 0.32 
 
43 
 
 11.38 ± 0.38  
 
31 
0.30 ± 0.43  
(-0.71, 0.24c) 
 
(1.27, 0.26) 
 
B 
 
11.68 ± 0.33  
 
41 
 
11.97 ± 0.38  
 
31 
0.29 ± 0.44  
(-0.67, 0.50d) 
 
(0.43, 0.26) 
Est A-B±SE   
(t, p) 
-0.60 ± 0.46  
(1.3, 0.19a) 
 
84 
-0.59 ± 0.54  
(1.1, 0.27a) 
 
62 
 
n/a 
 
(0.36, 0.78) 
 
Physical 
Fatigue+ 
 
A 
 
13.53 ± 0.31  
 
44 
 
13.23 ± 0.37  
 
31 
-0.30 ± 0.42  
(0.72, 0.24c) 
 
(2.26, 0.14) 
 
B 
 
12.42 ± 0.31 
 
41 
 
13.39 ± 0.35  
 
31 
0.97 ± 0.42  
(-2.27, 0.02d) 
 
(0.89, 0.45) 
Est A-B±SE  
(t, p) 
1.11 ± 44  
(-2.55, 0.01a) 
 
85 
-0.16 ± 0.51  
(0.31, 0.76a) 
 
62 
 
n/a 
 
(1.83, 0.14)  
 
Reduced 
Activity§ 
 
 
A 
 
13.18 ± 0.37 
 
44 
 
 13.21 ± 0.43  
 
31 
0.03 ± 0.52  
(-0.06, 0.48c) 
 
(2.05, 0.16) 
 
B 
 
12.42 ± 0.38  
 
40 
 
12.85 ± 0.41  
 
31 
0.43 ± 0.53  
(-0.81, 0.42d) 
 
(0.40, 0.76) 
Est A-B±SE   
(t, p) 
0.76 ± 0.51  
(-1.48, 0.14a) 
 
84 
0.36 ± 0.59  
(-0.61, 0.54a) 
 
62 
 
n/a 
 
(0.41, 0.74) 
 
LS-Means estimates displayed as means. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: Timepoint 2. t: 
t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.   ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for 
baseline race and depression. § Adjusted for baseline race and pain.  
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Table 4.11: Mixed Model Analysis of Psychological Variables from Baseline vs. Post-Training Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Post-Training (T2) 
Est µ± SE 
 
 
n 
 
Est. T2-T1±SE (t, 
p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Reduced 
Motivation^ 
 
 
A 
 
12.39 ± 0.37  
 
44 
 
11.97 ± 0.44  
 
31 
-0.42 ± 0.47  
(0.88, 0.19c) 
 
(0.39, 0.53) 
 
B 
 
11.62 ± 0.39 
 
41 
 
11.98 ± 0.44  
 
30 
0.36 ± 0.48  
(-0.73, 0.46d) 
 
(0.25, 0.86) 
Est A-B±SE  
(t, p) 
0.77 ± 0.54  
(-1.41, 0.16a) 
 
85 
-0.01 ± 0.62  
(0.01, 0.99a) 
 
62 
 
n/a 
 
(0.53, 0.66)  
 
LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1-
sided comparison between Baseline Assessment and Post-training Assessment. d2-sided comparison between 
Baseline Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T2: 
Timepoint 2. t: t-test statistic. f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by 
timepoint interaction term (1-sided). *Adjusted for baseline depression.      ^Adjusted for baseline pain. +Adjusted for 
baseline race. #Adjusted for baseline race and depression. § Adjusted for baseline race and pain. 
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Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-Up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, 
p) 
BDI Score* 
 
A 
 
21.9 ± 1.04 
 
44 
 
16.30 ± 1.34 
 
25 
-5.60 ± 1.46 
(3.84, <0.01c) 
  
(3.54, 0.06) 
 
B 
 
21.1 ± 1.08 
 
41 
 
20.32 ± 1.34 
 
25 
-0.78 ± 1.47 
(053, 0.59d) 
 
(5.73, <0.01) 
Est A-B±SE  
(t, p) 
0.8 ± 1.5 
(-0.52, 0.6a)  
 
85 
-4.02 ± 1.92 
(2.10, 0.037a) 
 
50 
 
n/a 
 
(2.42, 0.03)  
Perceived 
Stress Score* 
 
 
A 
 
22.46 ± 0.66 
 
44 
 
21.66 ± 0.82 
 
25 
-0.80 ± 0.83 
(0.96, 0.17c) 
  
(1.66, 0.20) 
 
B 
 
23.76 ± 0.69 
 
41 
 
23.35 ± 0.83 
 
25 
-0.41 ± 0.83 
(0.49, 0.62d) 
 
(2.83, 0.04) 
Est A-B±SE   
(t, p) 
1.30 ± 0.96 
(1.35, 0.18a) 
 
85 
-1.69 ± 1.18 
(1.43, 0.16a) 
 
50 
 
n/a 
 
(0.38, 0.76) 
General 
Fatigue+ 
 
 A  
 
12.51 ± 0.36 
 
44 
 
11.86 ± 0.45 
 
25 
-0.65 ± 0.47  
(1.40, 0.08c) 
  
(0.00, 0.97) 
 
B 
 
12.38 ± 0.36 
 
41 
 
11.85 ± 0.44 
 
25 
-0.53 ± 0.47  
(1.14, 0.26d) 
 
(2.48, 0.06) 
Est A-B±SE  
(t, p) 
0.13 ± 0.5   
(-0.25, 0.80a) 
 
85 
0.01 ± 0.63  
(-0.02, 0.99a) 
 
50 
 
n/a 
 
(0.45, 0.72) 
 
LS-Means estimates displayed. a2-sided comparison between groups. b1-sided test between groups. c1-sided comparison 
between Baseline t and Follow-up Assessment. d2-sided comparison between Baseline and Post-training Assessment. µ: 
Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 2. t: t-test statistic.  f: F test statistic. p: p-value. 
Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction term (1-sided). *Adjusted for baseline 
depression. ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted for baseline race and depression. § 
Adjusted for baseline race and pain. 
 
 
 
 
7
0
 
Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-Up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Mental 
Fatigue* 
 
 
A 
 
11.08 ± 0.32 
 
43 
 
 11.53 ± 0.41  
 
25 
0.45 ± 0.47  
(-0.98, 0.17c) 
 
(1.27, 0.26) 
 
B 
 
11.68 ± 0.33  
 
41 
 
11.50 ± 0.42  
 
25 
-0.18 ± 0.47  
(0.38, 0.71d) 
 
(0.43, 0.26) 
Est A-B±SE   
(t, p) 
-0.60 ± 0.46  
(1.3, 0.19a) 
 
84 
0.03 ± 0.59  
(-0.05, 0.96a) 
 
50 
 
n/a 
 
(0.36, 0.78) 
 
Physical 
Fatigue+ 
 
A 
 
13.53 ± 0.31  
 
44 
 
13.65 ± 0.40  
 
25 
0.12 ± 0.45  
(-0.25, 0.40c) 
 
(2.26, 0.14) 
 
B 
 
12.42 ± 0.31 
 
41 
 
12.80 ± 0.39  
 
25 
0.38 ± 0.46  
(-0.83, 0.41d) 
 
(0.89, 0.45) 
Est A-B±SE  
(t, p) 
1.11 ± 44  
(-2.55, 0.01a) 
 
85 
0.85 ± 0.56  
(-1.51, 0.13a) 
 
50 
 
n/a 
 
(1.83, 0.14)  
 
Reduced 
Activity§ 
 
 
A 
 
13.18 ± 0.37 
 
44 
 
 12.81 ± 0.47  
 
24 
-0.37 ± 0.55  
(0.62, 0.27c) 
 
(2.05, 0.16) 
 
B 
 
12.42 ± 0.38  
 
40 
 
12.82 ± 0.45  
 
25 
0.40 ± 0.55  
(-0.92, 0.36d) 
 
(0.40, 0.76) 
Est A-B±SE   
(t, p) 
0.76 ± 0.51  
(-1.48, 0.14a) 
 
84 
-0.01 ± 0.65  
(0.02, 0.98a) 
 
49 
 
n/a 
 
(0.41, 0.74) 
 
LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Follow-up Assessment d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. 
t: t-test statistic.  f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint 
interaction term (1-sided). *Adjusted for baseline depression. ^Adjusted for baseline pain. +Adjusted for baseline race. 
#Adjusted for baseline race and depression. § Adjusted for baseline race and pain. 
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Table 4.12: Mixed Model Analysis of Psychological Variables from Baseline vs. Follow-Up Assessments 
 
Outcome 
Group 
A=Intervention 
B=Control 
 
Baseline (T1) 
Est µ ± SE 
 
 
n 
 
Follow-Up (T4) 
Est µ± SE 
 
 
n 
 
Est. T4-T1±SE (t, p) 
Group (f, p) 
Timepoint (f, p) 
Group x Timepoint (f, p) 
Reduced 
Motivation^ 
 
 
A 
 
12.39 ± 0.37  
 
44 
 
12.39 ± 0.48  
 
25 
-0.002 ± 0.51  
(-0.00, 0.50c) 
 
(0.39, 0.53) 
 
B 
 
11.62 ± 0.39 
 
41 
 
12.14 ± 0.49  
 
24 
0.52 ± 052  
(-0.98, 0.32d) 
 
(0.25, 0.86) 
Est A-B±SE  
(t, p) 
0.77 ± 0.54  
(-1.41, 0.16a) 
 
85 
0.25 ± 0.69  
(-0.37, 0.71a) 
 
49 
 
n/a 
 
(0.53, 0.66)  
 
LS-Means estimates displayed as mean. a2-sided comparison between groups. b1-sided test between groups. c1-sided 
comparison between Baseline Assessment and Follow-up Assessment. d2-sided comparison between Baseline 
Assessment and Post-training Assessment. µ: Mean. SE: Standard error of the mean. T1: Timepoint 1. T4: Timepoint 4. t: 
t-test statistic.  f: F test statistic. p: p-value. Group x Timepoint: Type 3 test of fixed effects for group by timepoint interaction 
term (1-sided). *Adjusted for baseline depression.      ^Adjusted for baseline pain. +Adjusted for baseline race. #Adjusted 
for baseline race and depression. § Adjusted for baseline race and pain. 
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Table 4.13 Cohen’s D Estimates for Outcomes 
 
Outcome TP2-TP1 Pooled SD Cohen’s D1 TP4-TP1 Pooled SD Cohen’s D2 
HRV Coherence 0.4464 0.6392 0.70 0.4529 0.5456 0.83 
Pain Severity -0.2319 1.0277 -0.23 -0.9600 1.4549 -0.66 
Pain Interference -4.6472 8.7967 -0.53 -5.9922 16.0202 -0.37 
Pain Catastrophizing 0.5252 6.8512 0.07 -1.4800 7.5542 -0.20 
Paced Auditory Serial Addition Test 2.00 5.26 0.38 0.4800 4.5249 0.11 
Hopkins Verbal Learning Test 0.1613 4.8529 0.03 -0.8000 5.2144 -0.15 
Beck Depression Inventory -4.6472 8.7967 -0.53 -5.3600 8.9607 -0.60 
Perceived Stress 0.5927 4.9926 0.12 -0.3600 3.8794 -0.09 
General Fatigue 0.2333 3.2749 0.07 0.2833 3.3129 0.09 
Mental Fatigue 0.2667 2.8426 0.09 0.1633 3.1477 0.05 
Physical Fatigue -0.0667 2.7224 -0.02 .0383 2.7707 0.01 
Reduced Activity 0.1000 3.5025 0.03 -0.3982 3.2132 -0.12 
Reduced Motivation 0.3381 2.7766 0.12 0.2120 3.6650 0.06 
 
TP2-TP1: Difference score of group means between post-training and baseline, Pooled SD: Pooled Standard Deviation, 
Cohen’s D1: Cohen’s D Estimate between post-training and baseline, TP4-TP1: Difference score of group means between 
follow-up and baseline, Cohen’s D2: Cohen’s D Estimate between follow-up and baseline.  
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Table 4.14. Demographics by Completion Status 
 Total (n=76) Completers (n=50) Loss to Follow-up (n=26) p-value 
By Group 
Intervention 
Control 
 
38 (50) 
38 (50) 
 
25 (66) 
25 (66) 
 
13 (34) 
13 (34) 
1.00 
Age (years± SD) 55 ± 11 57 ± 9.9 50 ± 11.6 0.01 
Gender      n (%)    0.63 
Female (%) 26 (35) 19 (38)  7 (27)  
Male (%) 49 (65) 30 (60) 19 (73)  
Race    0.62 
Minorities (%) 47 (62) 32 (64) 15 (58)  
Caucasian (%) 29 (38) 18 (36) 11 (42)  
Education    0.14 
Less Than College 20 (26) 15 (30) 5 (19)  
College 47 (62) 27 (54) 20 (77)  
Graduate School 9 (12) 8 (16) 1 (4)  
Income    0.31 
Under $30,000 31 (41) 18 (36) 13 (50)  
$30,000-50,000 15 (20) 12 (24) 3 (12)  
$50,001 or more 25 (33) 15 (30) 10 (38)  
Refused 4 (5) 4 (8) 0 (0)  
Don’t know 1 (1) 1 (2) 0 (0)  
 
Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for categorical variables.  Pooled T-test used for 
continuous variables. n: number SD: Standard Deviation.   
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Table 4.15. Comorbidities at Baseline by Completion Status 
 
 Overall (n=76) Completers (n=50) Loss to Follow-up (n=26) p-value 
Hypertension    0.47 
Yes (%) 34 (45) 24 (48) 10 (38)  
No (%) 42 (55) 26 (52) 16 (62)  
Cancer    0.71 
Yes (%) 8 (11) 6 (12) 2 (8)  
No (%) 68 (89) 44 (88) 24 (92)  
Depression    0.34 
Yes (%) 35 (46) 21 (42) 14 (54)  
No (%) 41 (54) 29 (58) 12 (46)  
Anxiety    0.78 
Yes (%) 17 (22) 12 (24) 5 (19)  
No (%) 59 (78) 38 (76) 21 (81)  
PTSD    0.08 
Yes (%) 28 (37) 22 (44) 6 (23)  
No (%) 48 (63) 28 (56) 20 (77)  
Diabetes    0.78 
Yes (%) 19 (25) 12 (24) 7 (27)  
No (%) 57 (75) 38 (76) 19 (73)   
Fisher’s exact Test (2-sided) and Mantel-Haenszel Chi-Square used for categorical variables.  Pooled T-test used for 
continuous variables. n: number SD: Standard Deviation.  PTSD: Post Traumatic Stress Disorder. 
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Figure 4.1. Back-transformed log HRV Coherence LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 
vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post 
value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.   
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Figure 4.2. Back-transformed log LF Power LS Means ± SE msec2/Hz by treatment group and assessment. a1-sided, p 
< 0.05 vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 
vs Post value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.   
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Figure 4.3. Pain Severity Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value 
in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same 
group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at 
base of each bar.  Adjusted for race and depression at baseline. 
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Figure 4.4. LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value in the same group.  
b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same group.  d1-sided, p 
< 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at base of each bar.  
Adjusted for pain at baseline.  
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Figure 4.5. Pain Catastrophizing Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs 
Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post 
value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.  Adjusted for depression at baseline.  
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Figure 4.6. Back-Transformed non-steroidal anti-inflammatory drug use LS Means ± SE by treatment group and 
assessment. a1-sided, p < 0.05 vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same 
group. c1-sided, p < 0.05 vs Post value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of 
patients within each group and assessment indicated at base of each bar.    
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Figure 4.7. Back-Transformed Opioid LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline 
value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the 
same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment 
indicated at base of each bar.   
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Figure 4.8. Paced Auditory Serial Addition Test LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 
vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post 
value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.  Adjusted for race at baseline.  
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Figure 4.9. Hopkins Verbal Learning Test LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs 
Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post 
value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.  Adjusted for race at baseline. 
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Figure 4.10. Back-transformed Reciprocal Mean Reaction Time LS Means ± SE by treatment group and assessment. a1-
sided, p < 0.05 vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p 
< 0.05 vs Post value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each 
group and assessment indicated at base of each bar.  Adjusted for race at baseline.  
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Figure 4.11. Lapses LS Means ± SE log transformed then back-transformed by treatment group and assessment. a1-
sided, p < 0.05 vs Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p 
< 0.05 vs Post value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each 
group and assessment indicated at base of each bar.  Adjusted for Race at baseline.  
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Figure 4.12. Beck Depression Inventory LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs 
Baseline value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post 
value in the same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and 
assessment indicated at base of each bar.  Adjusted for depression at baseline.  
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Figure 4.13. Perceived Stress Scale LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline 
value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the 
same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated 
at base of each bar.  Adjusted for depression at baseline.  
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Figure 4.14. General Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline 
value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the 
same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated 
at base of each bar.  Adjusted for race at baseline. 
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Figure 4.15. Mental Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline 
value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the 
same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment 
indicated at base of each bar.  Adjusted for depression at baseline.  
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Figure 4.16. Physical Fatigue Score LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline 
value in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the 
same group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated 
at base of each bar.  Adjusted for race at baseline. 
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Figure 4.17. Reduced Activity LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value 
in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same 
group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at 
base of each bar.  Adjusted for race and pain at baseline.  
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Figure 4.18 Reduced Motivation LS Means ± SE by treatment group and assessment. a1-sided, p < 0.05 vs Baseline value 
in the same group.  b1-sided, p < 0.01 vs Baseline value in the same group. c1-sided, p < 0.05 vs Post value in the same 
group.  d1-sided, p < 0.01 vs Post value in the same group. n of patients within each group and assessment indicated at 
base of each bar.  Adjusted for pain at baseline.  
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CHAPTER 5 
DISCUSSION 
5.1 Overall Discussion 
 Results from this study indicate the receipt of HRVB can improve HRV 
coherence in veterans with chronic pain. HRV Coherence has been shown to help 
reduce clinical symptoms in other studies.8 For example, in a population of human 
immunodeficiency viral disease (HIV) patients, HRVB helped to reduce anxiety. 210 
HRVB helped improve emotional well-being and lower blood pressure in those with 
high blood pressure.211 Among physicians, HRVB helped reduce stress.212 In a 
group of congestive heart failure elderly patients, HRVB improved symptoms of 
depression.213  In the current study, receipt of the HRVB intervention was 
demonstrated by a statistically significant improvement in the HRV Coherence 
Ratio values. Large effect estimates of the HRV Coherence Ratio were noted when 
comparing baseline to post-training values (d=0.7) and baseline to follow-up 
(d=0.83) in the intervention group (Table 4.13). This is evidence that the 
biofeedback technique was received and sustained over the course of the study.  
 Both groups had a statistically significant improvement in Low Frequency 
Power. Improvement in LF for those in the control group may have been due to 
some sham-induced relaxation that also facilitated resonant frequency breathing 
in that group. This may be a result of sitting in a relatively quiet, calm, supportive 
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atmosphere while watching peaceful, static images of nature scenes. Improvement 
in LF power suggests an improvement in parasympathetic stimuli.214 Van der Zwan 
et al. conducted a study to evaluate efficacy of physical activity, mindfulness 
meditation, and HRVB with twenty adult volunteers aged 18-40 years old in 
Amsterdam who  reported stress with a PSS cut-off score of 17. Participants were 
stratified by gender and age then randomized into one of three groups. After a 
Baseline Assessment, five weekly training visits were conducted over 2-hours and 
a stair-stepped approach of intervention at home from 10-20 minutes over the five 
weeks. This was followed by a Follow-up Assessment. Van der Zwan et al. found 
no statistical differences between the three, and found all equally improved stress, 
anxiety, depression, and a general sense of well-being.25 Possibly, sitting 
passively observing nature scenes may mimic mindful meditation in which if that is 
the case, it would explain why the control group in the current study also improved 
their LF power. An increase in HRV coherence in the current study suggests the 
intervention group received and benefited from HRVB and that the intervention 
was sustained over four months. A strength of Van der Zwan’s study is the 
comparison of physical activity, HRVB, and meditation, however two limitations are 
the very small number of participants enrolled (n=20) and another is the short 
duration of the study.  It would be interesting to see if there were any differences 
in the groups over a longer period with additional assessments longitudinally and 
to see if one group sustained benefit longer than others. A benefit of the current 
study is the larger sample size (n=85) between two groups and was evaluated over 
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four months which demonstrated sustainability and improved duration of the HRVB 
intervention.  
5.2 Pain Discussion 
 The current study demonstrated a reduction in pain severity in the 
intervention group relative to the control group. A small effect estimate was noted 
between baseline and post-training (-0.23, Table 4.13) whereas a medium effect 
was noted between baseline and follow-up (d= -0.66, Table 4.13). This suggests 
that the use of HRVB has the potential to reduce pain severity in those who 
experience chronic pain. Further, pain interference was also statistically 
significantly reduced in those who received HRVB. A medium effect size was noted 
from baseline to post-training (-0.53, Table 4.13) and later a small effect size from 
baseline to follow-up (-0.37, Table 4.13) suggesting pain that interferes with daily 
activities may be reduced in those who practice HRVB.  This reduction in both 
outcomes can be attributed as a result of the benefit of HRVB. Both groups had a 
statistically significant reduction in pain catastrophizing scores from baseline to 
follow-up. When comparing group differences at follow-up, there was no 
statistically significant difference between the intervention group and the control 
group (p=0.28, Table 4.13). Small effect sizes for pain catastrophizing were also 
noted from baseline to post-training (0.07, Table 4.13) and baseline to follow-up (-
0.20, Table 4.13) in the intervention group (Table 4.13). The reduction may not 
have been completely due to HRVB, another possible factor to consider is the 
potential for a placebo effect. In a double-blinded, randomized control trial by 
Kapitza et al., 42 participants between the ages 18-70 years, with chronic low back 
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pain were enrolled into either an HRVB intervention or a placebo group. The 
participants were fitted for a machine to use at home in which the HRVB group had 
tailored resonance frequency breathing with feedback whereas the control group 
had no feedback and the device was set to about eight breaths per minute. 
Participants provided baseline data, 30 minutes of training at home for 15 days, 
follow-up at two weeks and at 3 months post intervention. A reduction in pain of 
approximately 25% was reported in the intervention group as compared to the 
control group. In the study by Kapitza, there were no dropouts, however in the 
current study, a loss-to-follow-up of about 33% was observed.21 
 In a separate study by Berry et. al., the use of HRV coherence biofeedback 
was randomly assigned in a pilot study of 14 U.S. military veterans with chronic 
pain allocating them to an HRVB intervention group and a placebo group. 
Following the Baseline Assessment, four weekly HRVB training visits were 
conducted prior to a Post-intervention Assessment. A greater reduction of pain 
was observed in the HRVB group as compared to the control group at post-
intervention (p=0.04) and a reduction in pain from pre- to post-intervention was 
reported in the HRVB group (p=<0.001).4  A limitation of the study is the small 
number of participants (n=14), along with the limited number of test outcome which 
used the BPI and PSS. However, similarities exist with the current study in that 
both populations were U.S. military veterans with chronic pain. Berry et al used 
four weeks of HRVB, whereas the current study prescribed six weeks Improved 
HRV coherence and reductions in pain were observed in the HRVB groups.  
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 In the present study, reductions in medication used were found only for non-
steroidal anti-inflammatory drug use in the intervention group and a slight but 
statistically significant reduction in opioid use in the intervention group between 
Post-training and Booster Assessment. This reduction in opioid use occurred after 
an unexplained increase in opioid use post-training and most likely is an artifact.  
The current study included all opioids in one category. Future studies should 
consider quantification of morphine equivalents and comparing quantity consumed 
before and after HRVB intervention. While a sustained reduction in opioid use was 
not achieved during the current study, the use of a longer study, possibly with a 
larger sample size could further elucidate if HRVB leads to reductions in pain and 
in opioid use. As chronic opioid use has potential for side-effects, so does 
separation from opioid use. In opioid addiction, on average, it takes a minimum of 
90 days of rehabilitation and a minimum of 12 months for methadone treatment to 
see limited benefit.94 Reductions in NSAID use may indicate that HRVB benefitted 
pain management among participants in a relatively short period of time. The 
results of the current study are consistent with other studies, which have also 
demonstrated a reduction of pain through the use of HRVB.4, 21-23, 39, 75 Hassett and 
associates assessed HRVB in a small sample (n=12) of female patients with 
fibromyalgia aged 18-60 years old from a rheumatology clinic utilizing ten weekly 
training sessions over three months with a pre- and post-assessment.22 
Participants were asked to practice for two 20-minute sessions per day and asked 
to refrain from caffeine or alcohol for 12 hours prior to assessments. Reductions in 
pain and depression were noted.22 Hallman and colleagues included 24 
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participants (22 female, 2 male) aged 25-50 years old with chronic shoulder and 
neck pain along with perceived stress, randomly assigned to intervention or 
control.  Reductions in pain were found with pre- and post-intervention 
measurements, 10 weekly training sessions, and practice at home 15 minutes per 
day for 5 days per week.39 Similarities exist with Hallman’s study and the current 
study.  Both were single-blind with an intervention and a control group. Both utilized 
personnel trained and credentialled in HRVB. 
 Multiple studies have used varying lengths of training with an HRVB trainer 
from 4-10 weeks and home practice of 15 to 20 minutes per day or twice a day. 
Improvements in HRV have been reported through receipt of HRVB however a 
standardized length of training and a standardized amount of home training have 
not been yet established.  Future studies should consider what is the minimum 
number of training sessions required to reach HRVB coherence and what is the 
minimum amount of home practice required to maintain that skill. 
5.3 Cognitive Discussion 
The PFC has been described as having an association with HRV and 
inhibitory control.215-217 High levels of HRV while resting have been associated with 
positive performance in executive function, cognitive flexibility, and in control of 
inhibition218, however as noted by Gillie and Thayer, individual differences may be 
linked to cognitive performance.215 HRVB has demonstrated improvement in 
cognitive performance in previous studies.4, 7, 8, 12 
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PASAT has been used in numerous studies to assess cognitive processing, 
speed of information processing, measures of sustained attention, concentration, 
and working or immediate memory. This multifactorial test requires both 
information processing speed and task completion.219 Both groups had  statistically 
significant improvements in PASAT at follow-up. When evaluating effect estimates 
for PASAT, initially a small to medium effect was noted (d= 0.38, Table 4.13) from 
baseline to post-training, whereas a smaller effect was found from baseline to 
follow-up (d= 0.11, Table 4.13). The increases in both groups over time may have 
been due to a learning effect.  
In a comprehensive review of the PASAT, numerous published comments 
appear to explain many of the findings in the current study.  For example, the 
PASAT is an auditory test or can be performed visually as a paced visual serial 
addition test (PVSAT). In the current study, it was an auditory test. The most 
common reported results are the correct number of responses for each trial when 
multiple trials are given or as with this study the sum of the correct number of 
responses overall. Others have suggested reporting the number of omissions and 
errors.219  Tombaugh suggests that most errors by the participant are the result of 
not answering as opposed to delayed answering. Some have noted that the 
participant may willingly skip a number to get the next one. This has been called 
“chunking” and is considered less taxing to the individual and could hinder 
identifying cognitive impairment. This may be where two numbers are summed, 
then they skip one or two numbers, and then resume. To overcome this, patterns 
could be identified and measured in “dyads” of consecutively provided correct 
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answers.219  A study examined the total number of correctly answered pairs of 
numbers. In some instances, participants keep track of numbers with their fingers, 
and differences may be present due to how the task is calculated rather than how 
quickly information is processed.219 In the current study, data was not collected if 
people were using their fingers to keep track of the last stated number. This author 
did however witness some participants whispering numbers to themselves to keep 
track of the last heard number.  
It has been suggested that due to the inherent stressful nature of the 
PASAT, frustration and anxiety are common even among cognitively intact 
individuals. With repeated exposure, a desensitization may occur, decreasing the 
novelty, and allowing for improved performance.  Increased comfort in performing 
the exam may occur when anxiety reduces with repeated exposure, allowing for 
increased concentration which may be a possibility for the findings in the current 
study.  Numerous authors have noted it to be unnecessarily stressful and some 
have even noted participants would rather have a lumbar puncture than go through 
the trials and tribulations of performing the PASAT.219 To reduce negative arousal, 
the participant should be notified in advance that the PASAT is a stressful test and 
that it should be administered at the end of a neurocognitive test battery. Even 
though this is not a pass or fail test, some people will feel as though they failed. 219  
Anecdotally, many subjects commented to this researcher of the difficulty of the 
PASAT and some expressed concern of having to perform it on their 2nd, 3rd, or 4th 
assessment having recalled their baseline experience.  
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In a convenient sample of undergraduate psychology students, 95 
participants were randomly assigned to a resonance frequency group (RF), a 
resonance frequency +1 additional breath/minute pace (RF+1), and a control 
group that sat quietly while conducting the PASAT. In that experiment, PASAT was 
used as a stressor while mood, HRV values, and blood pressure were assessed 
as outcomes. Systolic blood pressure remained lower and mood was more positive 
in the resonance frequency group relative to the controls while the resonance 
frequency group was not statistically different relative to the RF+1 group as the 
PASAT was conducted.220 
 When considering the results for the HVLT in the current study, both groups 
demonstrated improvement over time.  If improvement had only been seen in the 
intervention group, then it may have resulted from the HRVB training. Since both 
groups improved, the results cannot be fully attributed to HRVB. Small effect sizes 
were observed from baseline to post-training (d=0.03) and from baseline to follow-
up (d= -0.15, Table 4.13). A possible limitation of this study was that it did not 
measure delayed recall in which the participant would try to recall as many words 
as possible after a set number of minutes or after other tasks.  It would be 
interesting to assess delayed recall in addition to immediate recall in future studies.  
 Several studies have suggested that executive function is a direct reflection 
of HRV, and as executive demands increase, participants should exhibit lower 
HRV.158 However, other studies have not shown a direct correlation with increased 
executive demand and lower HRV.158  Luque-Casado et al. proposed that 
workload, or perceived difficulty of a task, along with the amount of time spent on 
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the task was more of an indicator for low HRV than the actual task itself. The 
National Aeronautics and Space Administration (NASA) developed a tool that was 
sensitive to mental workload. Using the NASA Task Load Index (NASA-TLX), 
Luque-Casado and colleagues evaluated subjective data of perceived mental 
stress through workload with objective HRV data.  Twenty-four undergraduate 
Spanish males age 18-28 were enrolled, conducted the PVT (vigilance), N-back 
test (measured working memory to respond to a stimulus if it matched a stimulus 
two trials before), a duration discrimination task (respond if a stimulus duration was 
longer or shorter compared to another), and an oddball condition (indicated if an 
infrequent characteristic displayed during a frequent characteristic), all while 
recording HRV measures. The oddball task was used as a control measure. 
Results displayed sensitivity of HRV to sustained attention. The researchers noted 
that HRV varied with the demands of the tasks and that lower HRV values were 
observed with the N-back test. It was noted that when they compared the oddball 
tests with the other three, the oddball and the N-back tests had twice the number 
of trials (in 12 minutes) as the PVT and the discrimination test. As there were more 
trials over a longer time, sustained attention in the N-back provided increased 
workload, thus influenced HRV more so than cognitive control, perceptual 
processing, working memory, or the individual tasks themselves.158 This 
corresponds with research conducted by Hansen, Johnsen, and Thayer which 
suggested that those who had high levels of  HRV, performed better with increased 
workload as compared to those with low levels of HRV124 and corresponds with 
research by Fairclough and Houston which noted that HRV reduced with longer 
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time-on-tasks.221 In the current study, HRV measurements were recorded prior to 
recording PASAT and HVLT measurements. As a result, the current study is not 
able to determine how HRV fluctuated during the PASAT and HVLT. Furthermore, 
as both the PASAT and HVLT are tests that require speaking, it would be nearly 
impossible to maintain a resonance frequency breathing rate while conducting 
those tests. Future studies should consider including recording HRV 
measurements while conducting cognitive tests which would allow for an initial 
resting assessment, an assessment with an increased workload during the 
cognitive tests, and then follow-up with a same-day post-assessment resting 
recording to allow for comparisons at rest, with increased workload and time-on-
task, and then a period of recovery. 
Although there were no differences in PASAT and HVLT outcomes between 
treatment groups, some of the participants did acknowledge they had a difficult 
time hearing the recording. Use of different speakers for the computer (both 
internal and external) provided the same difficulty for some participants. For 
continuity and consistency, the same recordings of words were used throughout 
this study.  For future consideration, quality of recordings must be ensured, and 
alternate speaker systems may be used.  This study did not inquire if the participant 
required hearing aids nor did it ensure they were wearing prescribed hearing aids 
at each of their visits for this study. A strength of this study is that both groups had 
the same list of words for the same assessment visits and a different list of words 
were used at each of the three assessments.  Lists of words were nouns that are 
common in daily life and are tangible such as corn, hammer, dentist, etc. These 
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are words that could be mentally visualized.  Many of the veterans told this 
researcher they noticed a pattern of three groups which helped them to improve 
on the second and third trial at each of the assessment visits. The most likely 
reason for improvements observed in both the intervention and control group in 
both the PASAT and HVLT is a practice effect.  
 Reaction time improved in the intervention group but not in the control 
group.  Reaction time is an aspect of cognitive processing of vigilant attention. 
Improvement in HRV using HRVB has the potential to synchronize neuro-
cardiovascular coupling, improve blood flow, and restore cognitive processes, 
thereby facilitating faster reaction time in those who utilize HRVB. In the current 
study, the PVT was conducted over a period of 10 minutes. This sustained 
attention with an increased workload of varying time intervals between stimuli 
further illustrates the importance of HRVB in cognitive ability to maintain vigilance 
to respond more quickly in the intervention group compared to the control group. 
Impaired error processing is caused by decreased attention and reduced attention 
from mental fatigue.222 When sustained attention is given to a task, mental fatigue 
may ensue, resulting in slower cognitive processing and increased errors.  When 
a person recognizes they made an error, reaction time slows.222 This has further 
implications for athletes, military and law enforcement members scanning for 
threats, and those in high risk occupations, such as airline pilots, where quick 
reaction to potential concerns is needed.  This study did not conduct resonance 
frequency breathing during PVT testing, however resonance frequency breathing 
in the HRVB group was conducted immediately prior to conducting the cognitive 
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tests. Only a couple of minutes would have lapsed between HRV measurements 
and moving four feet away to the computer for cognitive tests. It would be 
interesting to explore reaction time while performing resonance frequency 
breathing in future studies.  A hypothesis would be that performing resonance 
frequency breathing during PVT testing would facilitate faster reaction times.  
 As it pertains to the number of lapses, both groups demonstrated reduced 
lapses over time. This may be explained by a learning effect or an intention to want 
to perform better.  Furthermore, at the time of the final assessment (Follow-up), 
participants were exposed to two previous opportunities to gain experience and 
understand how the test is conducted.  Former military members are likely to be 
competitive and want to personally demonstrate self-improvement either for self-
fulfillment or to gain approval and positive affirmation from testers. This may 
explain why both groups demonstrated improvement over time. As noted by 
Prinsloo et al, often times participants sacrifice speed for accuracy or conversely 
sacrifice accuracy for speed.123 It is possible those in the control group 
demonstrated a reduction in lapses by sacrificing speed for accuracy. However, 
the number of lapses has been suggested to be directly influenced by fatigue and 
sleep deprivation.223 Therefore, it is conceivable that those who continued to be 
sleep deprived or fatigued may have been more likely to miss the visual stimuli, 
thus causing a lapse(s). 
 Psychomotor tasks and behavior are affected by time-on-task as well158 as 
is seen following sleep deprivation. 198 The vigilance and reaction time components 
of psychomotor vigilance tasks such as learning new skills and short-term memory 
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as well as fatigue and mental concentration are negatively affected by poor sleep, 
leading to increased time-on-task and increased lapses.198 The PVT is a high 
workload test demanding vigilant attention.198   Symptoms of sleep deprivation may 
be expressed as difficulty concentrating thus facilitating lapses and slower reaction 
times, changes in mood (stress and fatigue) and reduced motivation.198 LF power 
has been highly correlated with PVT lapses.224  In those who were sleep restricted, 
a correlation was found between HRV in the 0.01–0.08 Hz band and PVT 
lapses.225 However, the current study found no correlation between PVT lapses 
and LF power in the 0.04-0.15 Hz range, however both the intervention and the 
control group had decreases in the number of lapses.  
 The 10-minute version of the PVT was used in the present study. A longer 
version of the PVT leads to more lapses and longer reaction time due to waning 
attention and monotony.226 Lim et al198. note that when sleep is deprived, or 
subjects have prolonged wakefulness, reaction time is slower, more errors of 
commission are made, and is difficult for participants to stay focused on the 
task.198, 223, 226 Time-on-task has been previously reported to be inversely 
proportional to HRV measurements. While the focus of this analysis does not 
pertain to sleep measurements, future studies should consider how HRVB 
influences sleep quality and quantity in conjunction with cognitive performance.   
 A quasi-experimental descriptive study was conducted among 26 male 
PTSD Vietnam war veterans and 21 male normal Vietnam war veterans.227 
Outcomes included learning and memory utilizing an auditory-verbal learning as 
well as a visuospatial information test, in addition to an intelligence quotient (IQ) 
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test and arithmetic test. Those with PTSD recalled fewer words, demonstrated 
lower IQ than non-PTSD veterans and in those on psychoactive medications 
performed more poorly on the arithmetic testing than those not medicated. This 
study concluded that higher education may buffer development of PTSD.227 In a 
separate study, Vasterling examined 961 Soldiers preparing for the war in Iraq. 
Those who deployed demonstrated compromised attention and visuo-spatial 
memory and increased tension and confusion.127 It is unclear how many people in 
the current study deployed as deployment history was not gathered. Deployment 
history should be considered in future studies. While individual differences and 
experiences may be interesting to compare and could possibly confound a study, 
randomization in the current demonstrated effectiveness as there were no 
differences in PTST, anxiety, and other disorders between the HRVB and control 
groups. 
HRVB was used in a study of PTSD veterans including ten combat 
veterans; five with PTSD (intervention) and five without PTSD (controls). Patients 
in the intervention group were provided with four weeks of HRVB training. Attention 
and immediate memory were both statistically and clinically significant, with an 
increase in learned words in the HRVB group and a small decrease in words 
learned in the control group.8  
In summary, the PASAT, a measure of speed, attention, and the working 
memory component of executive function, demonstrated both groups improved.  
The HVLT, a measure of executive function, verbal and working memory, and to a 
lesser degree, attention, demonstrated both groups improved.  The PVT, a 
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measure of sustained vigilance, demonstrated an improvement in the HRVB 
intervention group. As both HVLT and PASAT have the potential for a learning 
effect, this may explain why an improvement was seen in both groups. An 
improvement was noted in the HRVB intervention group but not in the control group 
for the PVT which demonstrates the receipt of HRVB lead to an improvement in 
reaction time. Furthermore, stress loads in PASAT and HVLT may be higher than 
in PVT and attenuated benefits from the HRVB intervention. Future studies should 
evaluate in finer detail the cognitive functions and stress load of each of these tests 
while recording HRV measurements in a resting state, during task performance, 
and then followed by a resting state after testing to evaluate how much HRV 
changes from rest to stress and then how quickly, if at all, HRV returns to pretesting 
levels. As time-on-task is a crucial matter for cognitive function tests, the PASAT 
and HVLT were conducted over the course of about 4 minutes each, whereas the 
PVT was conducted over 10 minutes.  If longer versions of the PASAT and HVLT 
were conducted over 10 minutes for example, it would be hypothesized that those 
in the HRVB intervention group would demonstrate a significant improvement over 
and above those in the control group. Lastly, it would be hypothesized those in the 
HRVB intervention group who conduct resonant frequency breathing during the 
PVT would demonstrate less reduction in HRV during testing, would demonstrate 
decreased reaction time, and would result in a fewer number of lapses of the PVT 
as compared to the control group.  
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5.4 Depression, Stress, and Fatigue Discussion 
 In the present study, HRVB training improved depression symptoms 
immediately following the training and was evident two months later at the Follow-
up Assessment. Medium effect sizes were observed from baseline to post-training 
(-0.53, Table 4.13) and from baseline to follow-up (-0.60, Table 4.13). This finding 
is consistent with previous studies, all of which that had fewer participants. 
Improvement in depression was reported by Windthorst and colleagues in a study 
among 28 women with chronic fatigue and refractory depression who were 
randomized into an HRVB or a graded exercise training group. HRVB was 
provided for 10 training sessions and a reduction in both depressive symptoms 
and fatigue was reported over a five-month period.44 Another study reported 
improvements in major depressive disorder (MDD) in eight participants over a 10 
week period.40 To the author’s knowledge, the current study is the largest 
randomized controlled study of US military veterans to show a statistically 
significant improvement in depression due to HRVB.  
 There is a growing acceptance in the Western world for the benefits that 
can be derived from alternative stress-reducing therapies.25, 228 Van der Zwan and 
colleagues conducted a randomized HRVB trial among 76 individuals 18-40-years 
old. Outcomes included measures of depression, anxiety, and stress. The 
interventions entailed 20 minutes of daily exercise, meditation, or HRVB for five 
weeks. The largest effects were found with physical activity/exercise. Depression 
did not improve in the HRVB group. There were no statistically significant group 
differences for any of the outcomes. Small but statistically significant 
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improvements in psychological well-being were observed among the HRVB group. 
However, on average, those in the physical activity group exercised longer than 
the other groups spent in their intervention (meditation, HRVB), therefore protocol 
compliance differed.25  In the current study, protocol compliance was the same 
between groups and depression was improved in the intervention group indicating 
HRVB was successful at reducing depression in the intervention group. 
In a study of 32 female college students (ages 18-25 years) with MDD, 
HRVB was compared with treatment as usual (TAU), or a non-depressed control 
group. 41 MDD can be defined as a unipolar depressive disorder displaying five of 
nine symptoms most days over the course of two weeks: (depressed mood, loss 
of interest/pleasure, weight or appetite change, insomnia/hypersomnia, 
psychomotor retardation or agitation, loss of energy or fatigue, impaired 
concentration or indecisiveness, worthlessness or guilt, thoughts of death or 
suicidal ideation/attempt).229-231 Randomization for those with depression occurred 
into the HRVB+TAU or the TAU group. Five weekly HRVB training sessions were 
administered, and participants were encouraged to practice 15-20 minutes per day 
4-5 times per week. HRV measurements did not improve in the TAU (medication) 
group alone relative to HRVB+TAU. However, greater increases in HRV were 
found with HRVB+TAU (psychotherapy) and greater decreases in BDI scores 
among those with MDD compared to those without MDD.41 
Karavidas conducted an open-label research study in which all 11 
participants with MDD age 25-58 received HRVB training with 10 weekly sessions 
and encouraged to practice twice daily for 20 minutes each. A decrease in 
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depression severity and total BDI scores was noted in the group. A very large effect 
size (d=3.6) was noted in the Hamilton Depression Scale with a reduction in 
depression and statistically significant reduction in BDI from baseline to sessions 
4, 7, and 10.40 Consistent with the present study, BDI was reduced through the 
use of HRVB. A limitation of the study by Karavidas is the small number of 
participants. In comparison to the current study, nearly eight times as many 
participants were enrolled as with Karavidas’ study. A strength of the above study 
is the encouragement to practice HRV twice a day for 20 minutes as compared to 
15 minutes in the current study and ten training visits were conducted compared 
to six in the current study. It would be interesting to see if effect sizes were even 
more improved in the current study by either increasing the number of sessions or 
to increase the frequency and duration of home training visits.  
Zucker et al. conducted HRVB in a randomized pilot study of 38 people 
diagnosed with PTSD (ages 18-60), comparing HRVB and progressive muscle 
relaxation with a 4-week post-intervention follow-up and practicing 20-minutes per 
day averaging 5-6 practices per week. These participants were in a residential 
facility for substance abuse. A group by time interaction was found for 
improvements in SDNN. While no group by time interaction was found for PTSD 
symptom tests, reductions were found in PTSD symptoms in both groups from pre- 
to post-intervention. A reduction in BDI was found when it was used categorically; 
over 94% of the intervention group reduced in severity one category (mild 
depression=0-13, moderate= 14-19, and sever 29-63).36 Consistent with the 
current study, a decrease in depression was noted, however in the current study 
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an increase in SDNN was not found in the HRVB group. While Zucker et al did find 
a reduction in PTSD symptoms, the current study did not observe a statistically 
significant reduction in stress in the intervention group.  As it pertains to practice 
time, the current study recommended 15 minutes per day each day. It also is 
noteworthy that those with current substance abuse were excluded from the 
current study. Upon completion of any substance abuse rehabilitation program, 
potential participants had to remain sober for at least six months prior to being able 
to enroll. Substance abuse and withdrawal have direct implications on HRV 
measurements.232-234 
 No statistical differences in perceived stress were noted between groups in 
the current study, and small effect sizes were observed between baseline to post-
training as well as baseline to follow-up respectively (d= 0.12 and -0.09, Table 
4.13). There are several published studies pertaining to stress and HRVB among 
veterans focusing on PTSD patients that reported improvements in stress.36, 235-237 
Of the 85 participants who enrolled in this study, 38 were diagnosed with PTSD at 
baseline and they were equally distributed between the two groups. Perceived 
stress may be due to situations in the lives of the participants that are either chronic 
or may have occurred just prior to conducting the assessments.  For example, a 
participant may have received the intervention and demonstrated improvement in 
HRV coherence, however due to both chronic and acute situational stressors, the 
participant may not have felt that their stress level had improved.  Anecdotally, 
there was one specific participant in the intervention group that did just this.  Her 
HRV coherence significantly improved, however chronically, she was providing 
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care for her elderly mother while acutely, a 2-year-old niece she had previously 
provided care for died of congenital birth defects during this study. Consideration 
should be given to evaluate the composition of perceived stress in future studies. 
In a study by Ratanasiripong and researchers, HRVB was conducted with 
60 second-year baccalaureate nursing students in Thailand comparing a control 
group with an intervention group over five weeks. As they entered their clinical 
training, those who received HRVB demonstrated essentially no change in stress 
level, although a reduction in anxiety was observed relative to the control group.238 
 Similar to perceived stress, no statistically significant improvements were 
noted in general fatigue or the fatigue subscales in the present study, and small 
effect sizes were also noted among the fatigue assessments (Table 4.13). Smets 
and coauthors describe fatigue as a normal feeling resulting from physical exertion 
such as with exercise or due to insufficient sleep. While fatigue may be a symptom, 
Smets suggests that it could be a precursor to other disease outcomes and could 
also be analyzed as an outcome for treatments.172 The benefit of a 
multidimensional inventory to measure fatigue as compared to a single dimension, 
is that one person could feel mentally alert while being physically tired or a person 
could feel mentally tired but express physical stamina.172 Analyses of the five 
components of the MFI showed improvement in all five fatigue categories (general, 
mental, physical, activity, and motivation) after HRVB.44 As the follow-up was 
observed at five months post-intervention, it may be that fatigue takes a longer 
period of time to recover. In the current study, fatigue was measured up to four 
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months after Baseline Assessment.  Future studies should consider at least five 
months of follow-up to ascertain if fatigue takes longer to recover. 
5.5 Strengths and Limitations  
 As this is a randomized control trial, one study strength of this design is 
reduced confounding and selection bias. Differences noted between the groups at 
baseline were by chance alone. Another strength of this study is that subjects were 
screened for exposure to biofeedback. An assessment of HRV was made at 
baseline prior to HRVB exposure. Changes in HRV between the assessments 
were found to be causally related to HRVB training thus supporting the hypothesis 
that improvement in HRV can improve pain severity, pain interference, the need 
for non-steroidal anti-inflammatory drug use, as well as reaction time, and 
depression.  
A limitation of this study is that it only included US military veterans ages 
18+ and therefore may not be generalizable to all populations. Information bias 
could have resulted if participants had difficulty either recalling past information or 
were indecisive in how to respond to a question. Furthermore, information bias 
may have resulted if a participant decided not to answer (refused) a question (i.e. 
income) or may have been magnified if, despite the confidentiality imposed by the 
study protocol, they felt that information provided in this study may negatively 
impact their financial compensation from the VA.  Efforts were made to ensure 
completeness of all questionnaires at the time they were completed and then, 
using a neutral demeanor, participants were asked if the blank answer they 
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provided was what they meant to provide.  Staff were trained on how to transcribe 
and code variables for accuracy and they performed a 10% audit of data at various 
times. Interviewer bias was minimized by ensuring participant information was 
coded.  Participants were blinded to which group they were randomly enrolled and 
upon completion, and the control group was offered the opportunity to receive the 
HRVB training. Another limitation of this study was that participants who 
volunteered may have differed from those who did not volunteer to participate. A 
large limitation of this study due to the length of time involved over four months, 
was loss-to-follow-up.  Attempts were made to encourage participants to continue 
to remain enrolled and when a participant decided to voluntarily disenroll or to not 
make any more appointments, research staff inquired as to the reasoning to help 
in the final analysis. Over 500 veterans were screened prior to enrollment. Of 
these, many were not eligible due to uncontrolled hypertension or due to either a 
beta-blocker or calcium channel blocker medication. This precluded participation 
among some patients, yet exclusion of these patients helped prevent introduction 
of other biases. Those who were younger were more likely to be lost-to-follow-up 
rather than those who were older.  Otherwise, no differences were noted among 
those who completed the study versus those who were lost-to-follow-up in the 
demographics or comorbid diseases (Tables 4.14 and 4.15).  
A limitation of the PASAT has been noted with regional rates of diction. 
Those with language or speech difficulties may have been placed at a 
disadvantage and geographical or cultural speech patterns also may have 
influenced PASAT outcomes.219  For example, this study was performed in the 
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southeastern United States where some people may naturally speak with a slower 
cadence. This could be weighed against the fact that the study sample was 
comprised of former members of the military that grew up and served across the 
US and the globe. However, Tombaugh notes that obtaining low scores on the 
PASAT does not confirm pathology of the neurological system. Differences were 
not observed in PASAT outcome between groups. In the present study, 
improvements were found in both the HRVB group and the control group in the 
PCS, PASAT, HVLT, and the number of Lapses in the PVT. This may be due to a 
learning effect or that these tests may not be the best tests for this veteran 
population. 
In conclusion, HRVB is a safe, easily implemented, non-pharmacological 
technique that can be used virtually anywhere and can help in the self-regulation 
of symptoms such as pain and depression. Through the use of HRVB, HRV 
coherence improved, pain severity and pain interference decreased, a reduction 
in NSAID use was observed, depression decreased, and reaction time improved 
in the intervention group relative to the control group.  Larger studies conducted at 
multiple sites should be conducted to further determine the efficacy of HRVB 
among those with pain related symptoms in both veterans and the general 
population.  
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Figure A.1: 16-Week Study Timeline 
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Figure A.2: Instructions to calculating HRV Measures 
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Figure A.3 Participant Questionnaire 
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Figure A.4: CONSORT Flow Diagram 
 
